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A B S T R A C T
Background
Hydrocephalus is a common neurological disorder, caused by a progressive accumulation of cerebrospinal fluid (CSF) within the
intracranial space that can lead to increased intracranial pressure, enlargement of the ventricles (ventriculomegaly) and, consequently,
to brain damage. Ventriculo-peritoneal shunt systems are the mainstay therapy for this condition, however there are di@erent types of
shunt systems.
Objectives
To compare the e@ectiveness and adverse e@ects of conventional and complex shunt devices for CSF diversion in people with
hydrocephalus.
Search methods
We searched the Cochrane Central Register of Controlled Trials (2020 Issue 2); Ovid MEDLINE (1946 to February 2020); Embase
(Elsevier) (1974 to February 2020); Latin American and Caribbean Health Science Information Database (LILACS) (1980 to February 2020);
ClinicalTrials.gov; and World Health Organization International Clinical Trials Registry Platform.
Selection criteria
We selected randomised controlled trials or quasi-randomised trials of di@erent types of ventriculo-peritoneal shunting devices for people
with hydrocephalus. Primary outcomes included: treatment failure, adverse events and mortality.
Data collection and analysis
Two review authors screened studies for selection, assessed risk of bias and extracted data. Due to the scarcity of data, we performed a
Synthesis Without Meta-analysis (SWiM) incorporating GRADE for the quality of the evidence.
Main results
We included six studies with 962 participants assessing the e@ects of standard valves compared to anti-syphon valves, other types of
standard valves, self-adjusting CSF flow-regulating valves and external di@erential programmable pressure valves. All included studies
started in a hospital setting and o@ered ambulatory follow-up. Most studies were conducted in infants or children with hydrocephalus from
diverse causes. The certainty of the evidence for most comparisons was low to very low.
1. Standard valve versus anti-syphon valve
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Three studies with 296 randomised participants were included under this comparison. We are uncertain about the incidence of treatment
failure in participants with standard valve and anti-syphon valves (very low certainty of the evidence). The incidence of adverse events may
be similar in those with standard valves (range 0 to 1.9%) and anti-syphon valves (range 0 to 2.9%) (low certainty of the evidence). Mortality
may be similar in those with standard valves (0%) and anti-syphon valves (0.9%) (RD 0.01%, 95% CI -0.02% to 0.03%, low certainty of the
evidence). Ventricular size and head circumference may be similar in those with standard valves and anti-syphon valves (low certainty of
the evidence). None of the included studies reported the quality of life of participants.
2. Comparison between di3erent types of standard valves
Two studies with 174 randomised participants were included under this comparison. We are uncertain about the incidence of treatment
failure in participants with di@erent types of standard valves (early postoperative period: RR 0.41, 95% CI 0.13 to 1.27; at 12 months follow-
up: RR 1.17, 95% CI 0.72 to 1.92, very low certainty of the evidence). None of the included studies reported adverse events beyond those
included under "treatment failure". We are uncertain about the e@ects of di@erent types of standard valves on mortality (range 2% to 17%,
very low certainty of the evidence). The included studies did not report the e@ects of these interventions on quality of life, ventricular size
reduction or head circumference.
3. Standard valve versus self-adjusting CSF flow-regulating valve
One study with 229 randomised participants addressed this comparison. The incidence of treatment failure may be similar in those with
standard valves (42.98%) and self-adjusting CSF flow-regulating valves (39.13%) (low certainty of the evidence). The incidence of adverse
events may be similar in those with standard valves (range 0 to 1.9%) and those with self-adjusting CSF flow-regulating valves (range 0 to
7.2%) (low certainty of the evidence). The included study reported no deaths in either group in the postoperative period. Beyond the early
postoperative period, the authors stated that nine patients died (no disaggregated data by each type of intervention was available, low
certainty of the evidence). The included studies did not report the e@ects of these interventions on quality of life, ventricular size reduction
or head circumference.
4. External di3erential programmable pressure valve versus non-programmable valve
One study with 377 randomised participants addressed this comparison. The incidence of treatment failure may be similar in those
with programmable valves (52%) and non-programmable valves  (52%)   (RR 1.02, 95% CI 0.84 to 1.24, low certainty of the evidence).
The incidence of adverse events may be similar in those with programmable valves (6.19%) and non-programmable valves (6.01%) (RR
0.97, 95% CI 0.44 to 2.15, low certainty of the evidence). The included study did not report the e@ect of these interventions on mortality,
quality of life or head circumference. Ventricular size reduction may be similar in those with programmable valves and non-programmable
valves (low certainty of the evidence).
Authors' conclusions
Standard shunt valves for hydrocephalus compared to anti-syphon or self-adjusting CSF flow-regulating valves may cause little to no
di@erence on the main outcomes of this review, however we are very uncertain due to the low to very low certainty of evidence. Similarly,
di@erent types of standard valves and external di@erential programmable pressure valves versus non-programmable valves may be
associated with similar outcomes. Nevertheless, this review did not include valves with the latest technology, for which we need high-
quality randomised controlled trials focusing on patient-important outcomes including costs.
P L A I N   L A N G U A G E   S U M M A R Y
Ventriculo-peritoneal valves for hydrocephalus
Review question
What are the e@ects (benefits and harms) of di@erent types of shunt devices for people being treated for hydrocephalus?
Background
Hydrocephalus, known as 'water on the brain' is a disorder caused by the accumulation of cerebrospinal fluid in the cavities (ventricles)
deep within the brain. This causes an increase in the size of the ventricles and pressure on the brain that leads to brain damage. Ventriculo-
peritoneal valves are devices that drain the extra fluid from the brain into the peritoneal cavity,in the abdomen, where the fluid can be
absorbed (a ventriculo-peritoneal shunt). There are di@erent types of valves and the di@erent e@ects are unknown.
Study characteristics
We searched for the evidence up to February 2020. We included six studies with 962 participants evaluating: anti-syphon valves, di@erent
types of standard valves, self-adjusting cerebrospinal fluid flow-regulating valves and programmable valves. Most of the studies included
children with hydrocephalus with a follow-up between two to six years. Four studies did not specify their funding sources. One study was
funded by the manufacturer of the device and another study was funded by a foundation.
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Key results
We are uncertain about the di@erences in treatment failure between standard valves and anti-syphon valves, however, the incidence of
adverse events, mortality, ventricular size and head circumference may be similar. None of the included studies reported the quality of
life of participants.
We are uncertain about the di@erences in treatment failure and mortality in participants with di@erent types of standard valves. The
included studies did not report the e@ects of these interventions on quality of life, ventricular size and head circumference.
The incidence of treatment failure and adverse events may be similar in those with standard valves and self-adjusting cerebrospinal fluid
flow-regulating valves. The included study reported no deaths in either group early aOer the operation; we are uncertain about e@ects
beyond this period. The included studies did not report the e@ects of these interventions on quality of life, ventricular size reduction or
head circumference.
The incidence of treatment failure is probably similar in those with programmable valves and non-programmable valves, and the incidence
of adverse events and ventricular size may be also similar. The included study did not report the e@ect of these interventions on mortality,
quality of life or head circumference.
Quality of the evidence
The certainty of the evidence was mostly low to very low since the studies were poorly conducted, with a small number of participants.
Furthermore, many studies did not report critical outcomes such as mortality.
Ventriculo-peritoneal shunting devices for hydrocephalus (Review)
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Standard valve compared to anti-syphon valve for hydrocephalus
Standard valve compared to anti-syphon valve for hydrocephalus
Patient or population: participants with hydrocephalus
Setting: hospital procedure - outpatient follow-up (Iran, USA, Canada and France, Switzerland)
Intervention: Standard valve
Comparison: Anti-syphon valve







Treatment failure: morbidity asso-
ciated with shunt placement that
led to shunt revision
Follow-up: 2 to 6 years
There is uncertainty about the incidence of treatment failure
in participants with standard valve compared to anti-syphon
valves.
Range with standard valve: 43 - 55%




VERY LOW 1 2
Adverse events: morbidity related
to the shunt placement that has not
led to shunt revision
Follow-up: 2 to 6 years
The incidence of adverse events may be similar in those with
the standard valves compared to anti-syphon valves.
Range with standard valve: 0 - 1.8% for each type of adverse
event







In the early postoperative period (≤
30 days)
Mortality may be similar in those with standard valves com-
pared to anti-syphon valves.
Mortality in standard valve: 0%
Mortality with anti-syphon valve: 0.9%






Beyond the early postoperative pe-
riod (> 30 days)






Quality of life Not reported - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Ventriculo-peritoneal shunting devices for hydrocephalus (Review)
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Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded two levels due to high or unclear risk of bias in multiple domains of the included studies
2 Downgraded one level due to few participants and events in each study
3 Downgraded one level due to high and unclear risk of bias in multiple domains of the included study
4 Downgraded one level due to few participants and events in the included study
 
 
Summary of findings 2.   Comparison between di3erent types of standard valves
Comparison between different types of standard valves
Patient or population: participants with hydrocephalus
Setting: hospital procedure - outpatient follow-up (Mexico and Uganda)
Intervention and comparison: distal cleO valve (Biomed), Hakim ball-in-cone and spring, Chhabra and Codman-Hakim














There is uncertainty about the incidence of treatment failure in partici-
pants with different types of standard valves:
Garcia 1988 (84 participants) reported a similar incidence of early treat-
ment failure (7% vs 21% at 30 days) with the standard distal cleO valve
and the standard Hakim ball-in-cone and spring valve (RR 0.41, 95% CI
0.13 to 1.27).
Warf 2005 (90 participants) reported a similar incidence of treatment
failure (46% vs 42% at 12 months) with the Chhabra valve and the Cod-




VERY LOW 1 2
Adverse events: mor-
bidity related to the
shunt placement that




None of the included studies reported this outcome beyond those in-
cluded under "treatment failure".
(0 RCTs) -
Mortality
In the early postopera-
tive period (≤ 30 days)
There is uncertainty about the effects of different types of standard
valves on mortality.
Warf 2005 reported a 2% mortality with the Chhabra valve and 0% with
the Codman-Hakim micro precision valve (RD 0.02%, 95% CI -0.04% to
0.09%).
Garcia 1988 reported a 9% mortality with the standard distal cleO valve-
 and 0% mortality with the standard Hakim ball-in-cone and spring valve




VERY LOW 1 2
Mortality
Beyond the early post-
operative period (> 30
days)
We are uncertain about the effects of different types of standard valves
on mortality > 30 days.
Warf 2005 reported a 14% mortality with the Chhabra valve and 17% with




VERY LOW 1 2
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Quality of life Not reported - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RCT: randomised controlled trial; RD: Risk difference; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded two levels due to high or unclear risk of bias in multiple domains of the included studies
2 Downgraded one level due to few participants and events in the included studies
 
 
Summary of findings 3.   Standard valve compared to self-adjusting CSF flow-regulating valve for hydrocephalus
Standard valve compared to self-adjusting CSF flow-regulating valve for hydrocephalus
Patient or population: participants with hydrocephalus
Setting: inpatient procedure - outpatient follow-up (Canada, United States, France)
Intervention: standard valve
Comparison: self-adjusting CSF flow-regulating valve







Treatment failure: morbidity associ-
ated with shunt placement that led to
shunt revision
Follow-up: 2 years
The incidence of treatment failure may be similar in those
with the standard valve and the self-adjusting CSF flow-
regulating valve (RR 1.08, 95% CI 0.79 to 1.47).
Standard valve: 42%





Adverse events: morbidity related to
the shunt placement that has not led
to shunt revision
Follow-up: 2 years
The incidence of adverse events may be similar in those
with the standard valve and those with the self-adjusting
CSF flow-regulating valve.
Range with standard valve: 0–1.9%







In the early postoperative period (≤ 30
days)







Beyond the early postoperative period
(> 30 days)
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Quality of life Not reported - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; CSF: cerebrospinal fluid; RCT: randomised controlled trial; RR: Risk ratio.
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded one level due to high or unclear risk of bias in multiple domains in the included study
2 Downgraded one level due to few participants and events in the included study
 
 
Summary of findings 4.   External di3erential programmable pressure valve compared to non-programmable valves
External differential programmable pressure valve compared to non-programmable valves for hydrocephalus
Patient or population: participants with hydrocephalus
Setting: inpatient treatment - outpatient follow-up (USA)
Intervention: external differential programmable pressure valve
Comparison: other types of valve (any non-programmable valve pressure fixed pressure available on the market: Delta (Medtronic
PS Medical, Goleta Ca): 10%, other Medtronic PS Medical: 57%, other Codman/Johnson & Johnson: 8%, Orbis-Sigma (Cordis, Miami
Lakes, FL): 3%, others: 22%)







Treatment failure: morbidity associated with
shunt placement that led to shunt revision
Follow-up: 2 years
The incidence of treatment failure is probably
similar in those with programmable valves and
the non-programmable valves (RR 1.02, 95% CI
0.84 to 1.24).
Programmable valve: 52%






Adverse events: morbidity related to the
shunt placement that has not led to shunt revi-
sion
Follow-up: 2 years
The incidence of adverse events may be similar
in those with programmable valves and non-pro-
grammable valves (RR 0.97, 95% CI 0.44 to 2.15).
Programmable valve: 6.19%







In the early postoperative period (≤30 days)
Not reported - -
Mortality Not reported - -
Ventriculo-peritoneal shunting devices for hydrocephalus (Review)
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Beyond the early postoperative period (>30
days)
Quality of life Not reported - -
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the
relative effect of the intervention (and its 95% CI).
CI: Confidence interval; RCT: randomised controlled trial; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the ef-
fect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the
effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the
estimate of effect
1 Downgraded one level due to high or unclear risk of bias in multiple domains in the included study
2 Downgraded one level due to few participants and events in the included study
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B A C K G R O U N D
Description of the condition
A specialised fluid system circulates around the central nervous
system, providing structural and nutritional support for the brain
and spinal cord. The fluid is a modified filtrate of the blood called
cerebrospinal fluid (CSF), and is produced by groups of ependymal
cells, found in the brain and spinal cord, and concentrated in
the four choroid plexuses situated in the cerebral ventricles (four
normal cavities) of the brain (Champney 2016; Wolburg 2010). The
total CSF volume at any time is approximately 150 mL, of which 125
mL is produced inside the brain. The rate of production is 0.35 mL to
0.40 mL per minute. CSF flows from the lateral ventricles to the third
ventricle and then through the aqueduct to the fourth ventricle.
AOer that, it leaves the ventricular system through three foramina:
two laterally placed (foramina of Luschka) and one medially placed
(foramen of Magendie) to circulate in the subarachnoid space
(which is a layer of connective tissue between dura matter and the
brain surface) and, finally, it is absorbed into the venous system,
through the arachnoid villi (an absorption system in the layer
covering the brain) (Mancall 2011).
Hydrocephalus, known colloquially as 'water on the brain' or
'dropsy on the brain', is a common neurological disorder, caused
by a progressive accumulation of CSF within the intracranial space
that can lead to increased intracranial pressure, enlargement
of the ventricles (ventriculomegaly) and, consequently, to brain
damage. It results from problems with CSF production, circulation
or reabsorption. The incidence of hydrocephalus in the USA
lies between one and 32 cases per 10,000 births, depending
on the definition used and the population studied (Jeng 2011;
Kahle 2015). The most recent estimate of incidence comes from
a large, population-based study of idiopathic (unknown cause)
infantile hydrocephalus in Denmark over a 30-year period, which
documented 1.1 cases per 1000 births (Munch 2012; Tully 2014).
Hydrocephalus can be classified into communicating and non-
communicating types on the basis of its pathophysiology. The
non-communicating type, also called obstructive hydrocephalus,
can appear in the early foetal stage as part of certain congenital
malformations (such as aqueductal stenosis, Chiari malformation),
or associated with a broad spectrum of brain malformations,
which prevent the normal flow of CSF around the brain, and
its subsequent reabsorption. Hydrocephalus may also occur
secondary to an obstruction of the CSF circulation caused
by a tumour located in the fluid-producing cavities of the
brain (ventriculi). By comparison, communicating hydrocephalus
results from a deficit in CSF reabsorption, for example, in post-
meningitis hydrocephalus. Haemorrhage in preterm infants can
cause hydrocephalus by two mechanisms: acute obstruction by
a blood clot or a delayed reabsorption caused by thickening
of arachnoids, the inner layer of the meninges (Petre 2010).
Although infrequent, hydrocephalus can also be associated with an
overproduction of CSF, as in the case of a choroid plexus papilloma,
which is a type of benign intraventricular tumour.
Normal Pressure Hydrocephalus (NPH) is a condition first reported
in adults that refers to a chronic symptomatic hydrocephalus with
a normal CSF pressure (i.e. less than 18 mmHg) (Adams 1965). The
condition is defined by a clinical triad of symptoms: dementia,
gait di@iculties, and urinary urge incontinence in the presence of
ventriculomegaly documented by computed tomography (CT) or
magnetic resonance imaging (MRI) (Ziebell 2013; Halperin 2015).
There are signs in the magnetic resonance images that di@erentiate
NPH from other types of hydrocephalus, specifically, the amount of
interstitial oedema surrounding the lateral ventricles (which should
be minimal or absent), and the presence of brain deep white matter
ischaemia (inadequate blood flow) also known as small vessel
ischaemia or leukoaraiosis (Bradley 2015). In order to avoid overlap
with other Cochrane Reviews, this review did not include people
with NPH (Esmonde 2002; Tudor 2015; Ziebell 2013).
Signs and symptoms of hydrocephalus depend on the cause of the
condition and time of presentation. In congenital hydrocephalus,
patients present at birth with macrocephaly (overly large head),
scalp vein distension, a bulging fontanelle and diastasis of sutures
(stretching of fibrous joints between bones in the skull). These
can be correctly evaluated using reference tables developed
by measuring the circumference of the head of many children
at di@erent ages that are considered to establish the normal
parameters of head growth. Using this simple tool, rapid head
growth as a result of hydrocephalus can be detected clinically
(O'Neill 1961). Patients with hydrocephalus may also present with
Parinaud´s phenomenon, which is an inability to raise the eyes
upwards, also known as 'Sunset Sign', caused by an increased
pressure on the tectal plate, which is the area of the midbrain
where the oculomotor nerve originates. Symptoms in patients
with acquired hydrocephalus (obstructive, post-infectious, or post-
haemorrhagic) constitute the intracranial hypertension syndrome
which includes headache, vomiting and drowsiness (Petre 2010).
The appearance of these signs and symptoms of intracranial
hypertension is what di@erentiates developing hydrocephalus
from benign ventriculomegaly (dilation of the lateral ventricles in
the brain without causing an increase in the CSF pressure and,
therefore, without risk of brain damage).
In addition to physical examination and assessment of symptoms,
confirmation of diagnosis occurs by means of imaging studies
that show enlargement of ventricles. For newborns and infants,
ultrasonography is frequently used because it can be done at
the bedside and is radiation-free. Nevertheless, it is an operator-
dependent technology and does not assess the posterior fossa
(intracranial space occupied by the cerebellum and brain stem),
which sometimes makes it di@icult to establish the cause of the
hydrocephalus. For older children and adults, CT or MRI of the brain
is usually used (Carey 1994).
Since Hippocrates in the fiOh century BC, a poor understanding of
the pathophysiology of hydrocephalus contributed to the failure of
the early, and occasional attempts at therapy (Whytt 1768). In 1908,
Payr introduced the first ventriculo-venous shunt for drainage,
which consisted of a vein graO that led from the ventricles directly
into the sagittal sinus (a vein that surrounds the top of the brain
from front to back) and jugular veins (Mccullough 1990). In the same
year, Kaush used a rubber conduit to drain the lateral ventricle into
the peritoneal cavity (Kausch 1908), but the medical community
received this innovation with little enthusiasm. Research for more
e@ective treatments followed, and eventually the placement of
intracranial shunts was tested. E@orts to drain the excess CSF
into other body cavities have also been considered; for example,
Matson and colleagues at Boston Children´s Hospital first reported
a ureteral diversionary procedure (Matson 1949).
The early twentieth century was a period in which knowledge of
hydrocephalus, its diagnosis, and strategies for treatment evolved.
Ventriculo-peritoneal shunting devices for hydrocephalus (Review)
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Between January 1938 and December 1957, an observational,
case-series study, documented the progress of 182 patients with
congenital or acquired (early aOer birth, due to trauma or infection)
hydrocephalus, who were not operated on. By the end of the study,
only 81 patients were alive, and these had spontaneously arrested
hydrocephalus, that is, a gradual slowing of the rate of head
growth with a reduction in fontanelle tension and improvement
in the patient's general condition. Patients with comorbidities,
such as myelomeningocele or Chiari malformation, had the worst
prognosis (Laurence 1962). Since the introduction of an e@ective
therapy for the symptoms of hydrocephalus in 1956, when the first
shunt system became available, mortality rates have fallen from
around 45% to 53% - depending on the case series concerned -
to 15% (Hagberg 1962; Jansen 1985; Laurence 1967; Yashon 1963).
Morbidity rates have also significantly improved, with up to 42%
of treated hydrocephalus patients enjoying a normal lifestyle aOer
receiving shunts (Hirsch 1994).
The breakthrough that launched the modern era of surgical
treatment for hydrocephalus was the introduction of valve-
regulated shunts and biocompatible synthetic materials in 1952
(Lifshutz 2001). That same year, Nulsen, Spitz and Holter, reported
the successful use of a ventriculo-jugular shunt regulated by a
spring and ball valve (Drake 1995), and almost simultaneously,
Pudenz and colleagues, created a silicone one-way slit valve
(Pudenz 1957). The development of the valve system and the
availability of new biocompatible materials made it possible to
divert CSF safely and reliably, and to avoid the many complications
associated with unregulated CSF drainage.
Despite this degree of innovation, these devices were not exempt
from shunt failure, which represents a serious complication. The
most common causes of shunt malfunction include over- and
under-drainage, mechanical mismatch (Inadequate selection of
the pressure in a programmable valve or inadequate selection
of the valve in relation to the type of hydrocephalus), occlusion
(blocking) of the shunt and valve failure. These problems are
largely resolved by replacing the valve or parts of the shunt,
and sometimes by finding alternative drainage locations (for
example, using the circulatory system or the pleural cavity in
patients in whom the peritoneal cavity can not be used because of
peritoneal inflammatory diseases or surgical sequelae) as well as
with innovations in valve designs (Stein 2008).
Although implant of ventriculo-peritoneal shunts is the standard
treatment for patients with hydrocephalus, in the 1990s,
an additional method to treat hydrocephalus without the
use of a prosthetic device became available. Endoscopic
third ventriculostomy (ETV) is a minimally invasive procedure
originally introduced by Dandy in 1922. During the procedure,
a neuroendoscope is introduced, through a burr hole, into
the lateral cerebral ventricles and a hole is made within the
third ventricle to enable intracerebral ventricles to communicate
with the subarachnoid spaces. This procedure leads to a more
physiological circulation of CSF and is a well established treatment
for non-communicating hydrocephalus in some neurosurgical
units (Schroeder 1999). Risk of harms related to treatment is
always present, depending on the procedure. Shunts may have
complications related to placement, such as brain haemorrhages,
brain damage, infections, coma, and even exceptionally, death
(Smith 2004). In addition, there is an important and permanent risk
of shunt malfunction. On the other hand, ETV may also carry serious
complications including vascular injuries, hypothalamic injury
(brain damage), and occasional death, as has been reported (Drake
2006; Hader 2002). Due to the lack of clinical trials comparing both
strategies, the decision about whether to use ETV or ventriculo-
peritoneal shunts remains a topic of considerable debate (Cheng
2015; Limbrick 2014,Texakalidis 2019).
Description of the intervention
This review focused on the placement of various types of
ventriculo-peritoneal shunts for the treatment of hydrocephalus.
We define a ventriculo-peritoneal shunt as a system composed
of a ventricular catheter, which is usually inserted into one of
the cerebral lateral ventricles and is attached to both a valve
and a distal catheter (at the other end of the system), which is
implanted within the peritoneal cavity (abdomen) where CSF is
finally reabsorbed (ICD-9-CM 2004; Patwardhan 2005).
Ventriculo-peritoneal shunting is a complex surgical intervention.
This procedure is usually performed by an experienced
neurosurgeon, in the sterile conditions of an operating theatre, and
with the use of general anaesthesia. In the most commonly used
surgical technique, the patient lies on the operating table in the
supine position (lying on his back) with his head turned to one
side. Using sterile instruments, the surgeon makes two incisions.
One is made on the scalp in order to expose the posterior parietal
part of the skull (above and behind the ear), followed by a burr
hole through the skull and a small opening in the dura (membrane
that covers the brain), to access the dilated lateral ventricle with a
catheter. The second incision is made in the skin of the abdomen;
from there a tunnel is formed under the skin towards the skull
incision, and through this tunnel the distal catheter is passed. This
catheter is subsequently connected to the valve part of the shunt.
The ventricular catheter is also connected to the valve, which, in
turn, is fixed to the periosteum (connective tissue around the skull).
Finally, the distal end of the abdominal catheter is placed into the
peritoneal cavity, into which the CSF is drained (Warf 2005).
Valves are the most important part of the system, and there are a
variety of valve systems available that o@er fixed pressures, anti-
siphon devices, and programmable and  self-adjusting CSF flow-
regulating  capabilities (Ames 1967; Kaiser 1992; Lumenta 1990;
Ojemann 1968).
Fixed di@erential pressure (DP) valves are considered to be the first
generation of valves. When pressure builds up inside the tubing,
a slit is forced to open and CSF is allowed to flow outwards.
Only unidirectional flow is permitted since an increase in external
pressure closes the slit. The opening pressure is determined by the
thickness of tubing walls. They are commonly classified according
to the opening and closure pressures: low pressure (20 mm H2O to
40 mm H2O), medium pressure (40 mm H2O to 70 mm H2O) and high
pressure valves (80 mm H2O to 100 mm H2O) (Post 1985)
Second-generation valves include DP valves with flow-regulating
devices, valves with anti-siphon mechanisms and programmable
DP valves. Flow-regulating devices limit CSF flow through the valve
by progressively narrowing its orifice in response to increasing
intracranial pressure (ICP), as a pressure sensitive ring moves along
a variable-diameter rod. Its aim is to prevent both postural and
vasogenic  (mediated by blood vessels) over-drainage occurring
during rapid eye movement (REM) sleep, physical exertion,
coughing, and other physiological conditions (Hanlo 2003).
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Through an increase in flow resistance, anti-siphon devices
counteract the e@ect of hydrostatic negative pressure when the
patient stands in a vertical position. The aim of this system is to
provide performance characteristics that simulate those of normal
CSF absorption, while allowing the regulation of ICP  in a fashion
similar to that seen in healthy individuals when they change their
head position from horizontal to vertical (Baird 2014; Watson 1994).
Programmable variable pressure valves allow the selection of
di@erent opening pressures (between 30 mm H2O and 200 mm H2O
in intervals of 10 mm H2O). The opening pressure can be selected
through a percutaneous noninvasive magnetic programmer that
manages valve pressure according to the patient's clinical
and radiological evolution in terms of ventricular size. This
permits avoidance of over-drainage and its consequences, which
include slit (shaped) ventricles (accompanied by headaches) and
retardation of cranial vault growth (secondary craniosynostosis)
(Baird 2014; Miyake 2016; Xu 2013).
Finally, third-generation valves include DP programmable and anti-
siphon or gravitational systems combined in the same device. The
DP unit allows the selection of an opening pressure between 0 to 20
cm H2O, with the possibility of a transcutaneous adjustment. Unlike
anti-siphon systems, which use a fixed pressure, the gravitational
unit can be set to opening pressures of 15 cm H2O, 20 cm H2O, 25
cm H2O, or 30 cm H2O, which cannot be changed aOer placement.
This kind of device increases the opening pressure of the shunt
by blocking the inlet flow using a gravity-assisted ball bearing.
These devices must be placed vertically in order to counteract the
siphoning e@ect of negative hydrostatic pressures when the patient
is standing (Rohde 2009).
How the intervention might work
The balance in production, circulation, and reabsorption of the
CSF has a key role in the Monro-Kelly hypothesis (Champney 2016;
Lee 2009). This states that a stable ICP is the result of a rigid
sphere (cranium) occupied by a non-compressible volume of brain
tissue, blood and cerebrospinal fluid, which must remain constant.
Although physiological fluctuations can occur, these are related to
reciprocal changes in the amount of blood and CSF at a given time
(Han 2005). ICP varies during the day; normal values are between
7 mmHg to 15 mmHg in a supine adult. Fluctuations are regulated
primarily by cranial venous system blood volumes (CVSBV). As a
result of gravity, CVSBV diminish when a person is upright. A drop
in blood volume causes a retraction in brain tissues away from
the normal CSF filled ventricles, causing a drop in ICP. Production
of CSF also fluctuates during the day, but, as there is a balance
between production and reabsorption, the ventricular size remains
stable. There are also variations in CSF flow rate at night, with
periods of highest flow rate occurring during REM sleep (Watson
1994).
Normally, CSF is produced, circulates, and is reabsorbed within
the craniospinal space. Changes in body position between the
horizontal and vertical entail transfer of the CSF and blood from
the cranial compartment to the spinal compartment in a balanced
fashion. When a ventriculo-peritoneal shunt is in place in a
person with hydrocephalus, this balance is broken and hydrostatic
pressure plays an important role (Kurtom 2007). Valves provide a
resistance mechanism within the shunt system, which serves to
control ICP more than CSF flow in patients with hydrocephalus
(Miyake 2016).
In the developmental stage, shunt systems were synonymous with
CSF diversion to provide a rapid decrease in ICP, with very little
attention given to the cause of hydrocephalus. This approach
produced good early results in terms of resolution of ventricle
enlargement and reduction of ICP, but complications related to
over-drainage such as subdural haematomas (a type of blood clot
that forms surrounding the brain)  shunt failures due to catheter
obstruction, multiple shunt revisions and infections did appear
(Symss 2015).
Valve technology has evolved to demonstrate a more adequate
understanding of the physiological balance that needs to be
achieved in the production, circulation and reabsorption of
CSF. As a result, modern valves decrease ICP, as well as
reducing brain damage and shunt-related complications. Since
the first fixed-pressure shunts, like those of Holter and Pudenz
(Drake 1995; Pudenz 1957), shunt systems, and especially valves,
have evolved to incorporate flow-regulating, anti-siphon and
gravitational components that are designed to avoid the over-
drainage that can be caused by changes in patient position
(Czosnyka 1998).
Why it is important to do this review
Hydrocephalus is a common chronic neurological disease that
places a significant burden both on individuals and society as
a whole.The cost of its medical treatment is not completely
understood, but appears to be increasing (Pikus 1997). The
National Inpatient Sample (NIS) database, a nation-wide survey
in USA healthcare facilities, identified that in 2000 the three
most common causes of admission for hydrocephalus were: shunt
malfunction (40.7%), non-communicating hydrocephalus (16.6%),
and communicating hydrocephalus (13.2%). The most common
procedures that resulted from these hospitalisations were the
placement of a shunt (43.4%) and shunt replacement (42.8%).
The total costs of shunt-related procedures were estimated to be
approximately one billion USD (Patwardhan 2005).
Additionaly, a longitudinal study between 1997 and 2003 found
an increasing proportion of older children were admitted with
shunt malfunctions, and, when hydrocephalus treatment and its
complications were compared with other chronic illness, such as
cystic fibrosis, the inpatient utilisation (admissions, length of stay
and hospital charges) were higher for hydrocephalus (Shannon
2011).
In low- and middle-income countries, the treatment of
hydrocephalus may encounter additional challenges due to the
economic constraints that patients and families face to a@ord the
costs of acquisition, transportation and access to proper care (Warf
2005).
Although ventriculo-peritoneal shunting has been the most widely
used treatment for hydrocephalus in the twentieth century, it
is unclear whether the outcomes of shunting have improved
significantly over time, despite improvements in the understanding
of CSF physiology and the technological advancements in valve
design. The Hydrocephalus Clinical Research Network concluded
that in comparison with patients treated in the 1990s, there has
been a reduction in the risk of complications - assessed as the time
to first shunt failure - by about 18% (Kulkarni 2013). However, the
reasons for this improvement are not obvious, and thus, open to
interpretation.
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Despite this, long-term health and quality of life (QoL) outcomes
aOer shunt implant have been highly variable, and range from
patients leading a near normal life to those with physical, cognitive,
social and emotional impairments associated with disability. These
outcomes rely not only on the cause of hydrocephalus, but also on
treatment-related complications such as infections, haemorrhages
leading to brain haematomas, brain injury due to Inadequate
positioning of the catheter, coma, and occasionally, death (Smith
2004). They may appear shortly aOer surgery, and generally within
six months of shunt implantation or revision (Kulkarni 2007; Peters
2014; Sciubba 2007).
The main goal of physicians, researchers and engineers when
developing a new valve technology is to improve clinical outcomes
- both physical and mental - as well as reducing the likelihood
of shunt failure. A Cochrane systematic review published in 2013,
evaluated the e@ectiveness of flow-regulated versus di@erential
pressure-regulated shunt valves for adults with normal pressure
hydrocephalus (Ziebell 2013), but it was limited to two types of
valves in a specific group of participants. These reasons, and the
fast pace of technological progress, prompt the need for a high-
quality synthesis of the evidence for the e@ectiveness and safety
of common, fixed-pressure and other more complex ventriculo-
peritoneal shunt devices for people with hydrocephalus with
di@erent causes.
O B J E C T I V E S
To compare the e@ectiveness and adverse e@ects of conventional
and complex shunt devices for CSF diversion in people with
hydrocephalus.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials and quasi-randomised
controlled trials. We included studies regardless of their publication
status or language of publication.
Types of participants
People with clinical and imaging diagnosis of communicating
or non communicating, congenital or acquired hydrocephalus,
irrespective of cause or subtype.
No restrictions were made with respect to age, except for exclusion
of adults considered to have normal pressure hydrocephalus due
to clinical symptoms (dementia, gait dyspraxia, and incontinence)
and radiological signs (ventricular enlargement disproportionate
to the degree of cerebral atrophy), to prevent overlapping with
other Cochrane Reviews (Esmonde 2002; Tudor 2015; Ziebell 2013).
Types of interventions
We included studies with head-to-head comparisons between the
di@erent type of devices for ventriculo-peritoneal shunting listed
below:
• programmable valves: these allow selection of an opening
pressure value and are regulated by an external device, with or
without an anti-siphon element;
• gravitational (gravity-assisted) valves: these combine a
di@erential pressure unit that allows the selection of an opening
pressure between 0 and 20 cm H2O, with a gravitational unit
to counteract siphoning, while the opening pressure can be
regulated using telemetry;
• valves with an anti-siphon device: these counteract the e@ect of
hydrostatic negative pressure when the patient's body is in the
vertical position, through flow resistance;
• flow-regulating valves: this type of valve adaptively limits CSF
flow through the valve by narrowing its orifice progressively
in response to increasing ICP, to avoid the occurrence of
both postural and vasogenic over-drainage during normal
physiological conditions;
• conventional (standard) valve: CSF is drained only when ICP
rises above the fixed valve pressure.
Types of outcome measures
We did not use measurement of the outcomes assessed in this
review as eligibility criteria.
Primary outcomes
• Treatment failure: defined as morbidity associated with shunt
placement (slit ventricles (i.e. over-drainage), obstruction or
infections)) or progression of hydrocephalus detected by signs
or symptoms of intracranial hypertension or imaging studies
that led to shunt revision in the early postoperative period (≤ 30
days) or beyond the early postoperative period (> 30 days).
• Adverse events: morbidity related to the shunt placement that
has not led to shunt revision (e.g. subdural haematomas,
secondary craniosynostosis and microcephaly) in the early
postoperative period (≤ 30 days) or beyond the early
postoperative period (> 30 days).
• Mortality: defined as death for all causes in the early
postoperative period (≤ 30 days) or beyond the early
postoperative period (> 30 days).
Secondary outcomes
• Quality of life and health-related quality of life measured
according to a validated questionnaire, such as: the Medical
Outcomes Study (MOS) 36-Item Short-Form Health Survey
(SF-36) (Ware 2012), and EuroQOL-5D (EQ-5D) for adults
(Williams 1990), and the Child Health Questionnaire (CHQ)
(Landgraf 1999), or the Hydrocephalus Outcome Questionnaire
(HOQ) for children (Kulkarni 2004) in the early postoperative
period (≤ 30 days) or beyond the early postoperative period (>
30 days).
• Ventricular size reduction measured by cranial sonography or CT
scan in the early postoperative period (≤ 30 days) or beyond the
early postoperative period (> 30 days).
• Head circumference measured before and aOer placement
of the ventriculo-peritoneal shunt (occipitofrontal head
circumference) in the early postoperative period (≤ 30 days) or
beyond the early postoperative period (> 30 days).
Search methods for identification of studies
We performed a comprehensive search with no restrictions on the
language of publication or publication status.
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Electronic searches
We searched the following sources for eligible reports in any
language (Appendix 1):
• Cochrane Central Register of Controlled Trials (CENTRAL; most
recent issue);
• Ovid MEDLINE (1946 to February 2020);
• Elsevier/Embase (1974 to February 2020);
• Latin American and Caribbean Health Sciences Literature
database (LILACS; 1980 to February 2020);
• ClinicalTrials.gov (clinicaltrials.gov) (inception to 12.02.2020);
and
• WHO International Clinical Trials Registry Platform
(apps.who.int/trialsearch/) (inception to 12.02.2020).
We combined the Ovid MEDLINE search with the Cochrane Highly
Sensitive Search Strategy for identifying randomised trials in
MEDLINE, Ovid format (Lefebvre 2011).
This search strategy was adapted to search CENTRAL, Embase and
LILACS. See Di@erences between protocol and review.
Searching other resources
We identified other potentially eligible trials or ancillary
publications by searching the reference lists of retrieved included
trials, reviews, meta-analyses and health technology assessment
reports. We also contacted study authors of included trials to
identify any further studies that we may have missed. We contacted
drug and device manufacturers for ongoing or unpublished trials.
We also examined any relevant retraction statements and errata for
included studies.
To identify additional studies, we reviewed proceedings of the
annual meetings of the European Society of Pediatric Neurosurgery
(ESPN) and the  International Society of Pediatric Neurosurgery
(ISPN) for the last three years (Appendix 2).
We also searched the  source of grey literature, Open Grey
(www.opengrey.eu) (1980 to February 2020) (Appendix 1). See
Di@erences between protocol and review.
Data collection and analysis
Selection of studies
Independently, two review authors (SP, VV, or JVAF) scanned the
abstract, title, or both, of the records retrieved, to determine
which studies needed to be assessed further. Two review authors
(SP, VV, or JVAF) investigated all potentially relevant records as
full text, mapped records to studies, and classified studies as
included studies, excluded studies, studies awaiting classification,
or ongoing studies in accordance with the criteria for each
provided in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011a). We resolved any discrepancies
through consensus or recourse to a third review author (AC). If
resolution of a disagreement was not possible, we designated the
study as 'awaiting classification' and we contacted study authors
for clarification. We documented reasons for exclusion of studies
that may have reasonably been expected to be included in the
review in a 'Characteristics of excluded studies' table. We presented
an adapted Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) flow diagram showing the process of study
selection (Liberati 2009).
Data extraction and management
We developed a dedicated data abstraction form that we tested
ahead of time.
For studies that fulfilled the inclusion criteria, two review authors
(LIG, SP, VV, or JVAF) independently abstracted the following
information, which we provided in the 'Characteristics of included
studies' table.
• Study design.
• Study dates (if dates were not available then this was reported).
• Study settings and country.
• Participant inclusion and exclusion criteria.
• Participant details, baseline demographics.
• The number of participants by study and by study arm.
• Details of relevant experimental and comparator interventions
such as: manufacturer, device model and characteristics.
• Definitions of relevant outcomes, and method and timing of
outcome measurement, as well as any relevant subgroups.
• Sources of study funding.
• Declarations of interest by primary investigators.
We extracted outcome data relevant to this Cochrane Review as
needed for calculation of summary statistics and measures of
variance. For dichotomous outcomes, we attempted to obtain
numbers of events and totals in order to populate a 2 x 2
table, as well as summary statistics with corresponding measures
of variance. For continuous outcomes, we attempted to obtain
means and standard deviations or data necessary to calculate this
information. For time-to-event outcomes, we attempted to obtain
hazard ratios (HR) with corresponding measures of variance or data
necessary to calculate this information.
We resolved any disagreements by consensus, or, if required, by
consultation with a third review author (AC).
We provided information, including trial identifiers, about
potentially relevant ongoing studies in the table 'Characteristics of
ongoing studies'.
We attempted to contact authors of included studies to obtain key
missing data, as needed.
Assessment of risk of bias in included studies
Two review authors (SP, LIG, VV, or JVAF) assessed the risk of bias of
each included study independently. We resolved disagreements by
consensus, or by consultation with a third review author (AC).
We assessed risk of bias using the Cochrane 'Risk of bias'
assessment tool (Higgins 2011b). We assessed the following
domains:
• sequence generation (selection bias);
• allocation concealment (selection bias);
• blinding of participants and personnel (performance bias);
• blinding of outcome assessment (detection bias);
• incomplete outcome data (attrition bias);
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• selective outcome reporting (reporting bias); and
• other sources of bias.
We judged risk of bias domains as 'low risk', 'high risk' or 'unclear
risk' and evaluated individual bias items as described in the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011b). We presented a 'Risk of bias' summary figure to illustrate
these findings.
For performance bias (blinding of participants and personnel) and
detection bias (blinding of outcome assessment), we evaluated the
risk of bias separately for each outcome, and, when we reported our
findings in the 'Risk of bias' tables, we grouped outcomes according
to whether they were measured subjectively or objectively.
We also assessed attrition bias (incomplete outcome data) on
an outcome-specific basis, and grouped outcomes with like
judgements when reporting our findings in the 'Risk of bias' tables.
In addition, we summarised the risk of bias across domains for
each outcome in each included study, as well as across studies and
domains for each outcome.
Measures of treatment e3ect
We expressed dichotomous data as risk ratios (RRs) with 95%
confidence intervals (CIs). We reported risk di@erences (RDs) when
absolute risks in both groups were < 1%. We expressed continuous
data as mean di@erences (MDs) with 95% CI, unless di@erent studies
used di@erent measures to assess the same outcome, in which case
we would have analysed data as standardised mean di@erences
(SMDs) with 95% CI (re-expressed and presented as units of a
familiar measure). We expressed time-to-event data as hazard
ratios (HRs) with 95% CI.
Unit of analysis issues
The unit of analysis was the individual participant. If a patient
received more than one shunt during the course of a trial, we
considered the outcomes related to the first implanted device
only. If we had identified cluster-randomised trials, we would have
followed the guidance of the Handbook Section 23.1.3 (Higgins
2019). Cross-over studies were unlikely to be feasible.
Dealing with missing data
We obtained missing data from study authors, if feasible, and
performed intention-to-treat (ITT) analyses whenever possible;
otherwise, we performed available case analyses. We investigated
attrition rates, e.g. dropouts, losses to follow-up and withdrawals,
and appraised any issues of missing data critically.
Assessment of heterogeneity
We evaluated clinical diversity (clinical heterogeneity) across
studies by examining the description of the characteristics of
participants, interventions and outcome assessment from data
extracted (see Data extraction and management). In the event of
significant heterogeneity that could not be explained by subgroup
analyses, we did not report outcome results as a pooled e@ect
estimate in a meta-analysis, but provided a narrative description of
the results of each study.
We had also planned to identify  heterogeneity (inconsistency)
through visual inspection of the forest plots to assess the amount
of overlap of CIs, and the I2 statistic: this statistic quantifies
inconsistency across studies to assess the impact of heterogeneity
on the meta-analysis (Higgins 2002; Higgins 2003). We had planned
to interpret the I2 statistic as follows:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: represents considerable heterogeneity.
When we found moderate (or more) heterogeneity, we had planned
to attempt to determine possible reasons for it by examining
individual study and subgroup characteristics, as well as by
sensitivity analyses according to risk of bias domains.
Assessment of reporting biases
We attempted to obtain study protocols to assess selective
outcome reporting.
If we had included ten studies or more investigating a particular
outcome, we planned to use funnel plots to assess small study
e@ects. Several explanations can be o@ered for the asymmetry of
a funnel plot, including true heterogeneity of e@ect with respect
to trial size, poor methodological design (and hence bias of
small trials) and publication bias. We therefore interpreted results
carefully.
Data synthesis
Unless there was good evidence for homogeneous e@ects across
studies, we had planned to summarise data using a random-
e@ects model. We planned to interpret random-e@ects meta-
analyses with due consideration of the whole distribution of
e@ects. In addition, we planned to perform statistical analyses
according to the statistical guidelines contained in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011a).
For dichotomous outcomes, we planned to use the Mantel-
Haenszel method; for continuous outcomes, we planned to use
the inverse variance method; and for time-to-event outcomes, we
planned to use the generic inverse variance method to combine
final scores or change score of continuous outcomes. We used
Review Manager 5 soOware to perform some analyses (Review
Manager 2014).
Since we found incompletely reported outcome data and, in some
cases, clinical and methodological diversity, we also performed
a narrative synthesis of the available quantitative data following
the Cochrane Handbook's guidance (McKenzie 2019) and the latest
guidance on Synthesis Without Meta-analysis (SWiM) (Campbell
2020). Firstly, we grouped each comparison by valve type
(regardless of manufacturer or opening pressure) following our
initial protocol. Then we reported, when available, the absolute
number of events for each outcome and the corresponding
statistics (P values). If su@icient data were available, we reported
risk ratios or hazard ratios and their 95% confidence intervals or
risk di@erences when absolute risks in both groups were < 1%.
We summarised the results using vote counting based on direction
of e@ect, prioritising the findings from larger studies and, when
available, studies at low risk of bias. We assessed heterogeneity
qualitatively and followed GRADE methods for assessing the overall
quality of evidence and presenting results in 'Summary of findings'
tables.
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Subgroup analysis and investigation of heterogeneity
If we had at least 10 studies, we would have conducted subgroup
analyses according to the type of valve employed and also by
a number of factors prespecified below, as it is probable that,
given the heterogeneity of the causes of hydrocephalus, clinical
outcomes may depend on these subgroups:
• type of valve employed: programmable valve systems,
gravitational, anti-siphon, flow-regulating and standard valves;
• age of participant: paediatric participants (i.e. from birth to 18th
birthday) and adults;
• congenital or acquired hydrocephalus.
If there were su@icient studies, we used the test for subgroup
di@erences in Review Manager 2014 to compare subgroup analyses.
Sensitivity analysis
We had planned to perform sensitivity analyses in order to explore
the influence of the following factors (when applicable) on e@ect
sizes:
• restricting the analysis by taking into account risk of bias, by
excluding studies at high risk or unclear risk, in the following
domains: sequence generation (selection bias), allocation
concealment (selection bias), blinding of participants and
personnel (performance bias), blinding of outcome assessment
(detection bias), incomplete outcome data (attrition bias),
selective outcome reporting (reporting bias);
• by using the fixed-e@ect model instead of random-e@ects model
when moderate heterogeneity was present.
Summary of findings and assessment of the certainty of the
evidence
We presented the overall quality of the evidence for each outcome
aOer applying the methods of the GRADE Working Group (GRADE
Working Group 2004), which takes into account five criteria that
relate to internal validity (risk of bias, inconsistency, imprecision,
publication bias), and also to external validity, such as directness
of results (Guyatt 2008). For each comparison, independently, two
review authors (LIG and JVAF) rated the certainty of evidence
for each outcome as 'high', 'moderate', 'low', or 'very low' using
GRADEpro 2008. We resolved any discrepancies by consensus, or, if
needed, by arbitration by a third review author (AC).
For each comparison, we presented a summary of the evidence for
the main outcomes in a 'Summary of findings' table, which provides
key information about the best estimate of the magnitude of the
e@ect in relative terms and absolute di@erences for each relevant
comparison of alternative management strategies; numbers of
participants and studies addressing each important outcome; and
the rating of the overall confidence in e@ect estimates for each
outcome (Guyatt 2011; Schünemann 2011). If meta-analysis was
not possible, we presented results in a narrative 'Summary of
findings' table.
We created a 'Summary of findings' (SoF) table using the following
comparisons:
• Comparison 1: Standard valve compared to anti-syphon valve
• Comparison 2: Comparison between di@erent types of standard
valves
• Comparison 3: Standard valve compared to self-adjusting CSF
flow-regulating valve
• Comparison 4: External di@erential programmable valve versus
non-programmable valves
The SoF tables included the following outcomes:
• Treatment failure beyond the early postoperative period (> 30
days)
• Adverse events beyond the early postoperative period (> 30
days)
• Mortality in the early postoperative period (≤ 30 days)
• Mortality beyond the early postoperative period (> 30 days)
• Quality of life beyond the early postoperative period (> 30 days)
R E S U L T S
Description of studies
Results of the search
For detailed information about the results of the search, see Figure
1.  For this review, we screened 2034 records. We excluded 1989
records aOer title and abstract screening and obtained the full text
for 49 studies. We excluded 39 studies aOer the full-text assessment
(their characteristics are described in Characteristics of excluded
studies). We included six studies (nine records) in this review.
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Figure 1.   Study flow diagram.
 
Included studies
We included six studies with 962 participants (see Characteristics of
included studies).
Design
Four of the included studies were RCTs (Drake 1998; Garcia 1988;
Khan 2010; Pollack 1999) and two studies (Liniger 2003; Warf
2005) reported an inadequate method of randomisation (quasi-
randomised studies).
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Sample sizes
Median sample size was 87 participants (interquartile range 37 to
352). The smallest sample size was 27 (Liniger 2003) and the largest
sample size was 377 (Pollack 1999).
Setting
Since VP shunt requires a surgical procedure, all included studies
started in a hospital setting and o@ered ambulatory follow-up.
One study was conducted in Mexico (Garcia 1988), one study
was conducted in India (Khan 2010), one study was conducted in
Switzerland (Liniger 2003), one study was conducted in the USA
(Pollack 1999), one  study was conducted in Uganda (Warf 2005),
and one study was conducted in more than one country (USA,
Canada and France; Drake 1998).
Five studies were reported in the English language (Drake 1998;
Khan 2010; Liniger 2003; Pollack 1999; Warf 2005), and one study
was reported in the Spanish language (Garcia 1988).
Participants
Four studies were conducted in infants or children (Drake 1998;
Khan 2010; Liniger 2003; Warf 2005), one study was conducted in
adults (Garcia 1988), and one study was conducted in patients of
any age (Pollack 1999).
Interventions
Two studies compared the placement of a  standard valve versus
an  anti-siphon valve  (Khan 2010; Liniger 2003), two studies
compared two di@erent types of standard valves (Garcia 1988; Warf
2005), one study compared a programmable valve versus other
types of non-programmable valves (Pollack 1999), and one study
compared more than two types of valves: a standard valve, an anti-
siphon valve and a self-adjusting CSF flow-regulating valve (Drake
1998).
Outcomes
All studies reported the e@ects of the interventions on treatment
failure and adverse events. Three studies reported all-cause
mortality (Drake 1998; Garcia 1988; Warf 2005). Three studies
reported ventricular size reduction (Khan 2010; Liniger 2003;
Pollack 1999), two studies reported head circumference (Khan
2010; Liniger 2003). None of the included studies reported quality
of life.
Funding sources
Most studies (4/6 studies, 67%) did not specify their funding
sources. Drake 1998 was funded by Medtronic PS Medical (Goleta,
CA), Cordis Corp (Miami FL), British Columbia Health Research
Foundation and The Science Council of British Columbia (Burnaby
Canada), Mr. and Mrs. PA Woodward´s Foundation (Vancouver
Canada) British Columbia´s Children´s Hospital Telethon Clinical
Investigative Initiatives (Vancouver, Canada) British Columbia
´s Medical Services Foundation (Vancouver, Canada) Spina
Bifida Association of Canada (Winnipeg, Canada) and Spina
Bifida Association of British Columbia (Surrey, Canada).  Warf
2005 was funded by the International Federation for Spina Bifida
and Hydrocephalus and CURE International (which funds CURE
Children’s Hospital of Uganda).
Excluded studies
We excluded 39 reports aOer full-text assessment.  Two  reports
were duplicates that had not been identified in the previous
stages (Drake 1996; Drake 2000), one  was a letter (Czosnyka
2000), one was an  editorial (Hoshide 2017),  one was a  narrative
review (Drake 1998a), nine  studies were systematic reviews or
health technology assessments (ASERNIP-S 2014; Baird 2014; Del
Bigio 1998; Ito 2012; Li 2017; Rasul 2012; Wong 2012; Xu 2013;
Xu 2013a), three were in vitro studies (Czosnyka 1990; Czosnyka
2002; Portnoy 1976) and three  were randomised trials with
ineligible interventions (Mbabazi-Kabachelor 2019; Sinha 2012;
Sotelo 2005). The remaining 19 studies were excluded since they
were observational studies (mostly retrospective studies or case
series).
Risk of bias in included studies
All studies were deemed to be at unclear or high risk of bias (see
Figure 2 and Figure 3)
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias): Subjective outcomes: treatment failure, adverse events, quality of life
Blinding of participants and personnel (performance bias): Objective outcomes: mortality, head circumference, ventricular size
Blinding of outcome assessment (detection bias): Subjective outcomes: treatment failure, adverse events, quality of life
Blinding of outcome assessment (detection bias): Objective outcomes: mortality, head circumference, ventricular size
Incomplete outcome data (attrition bias): All outcomes
Selective reporting (reporting bias)
Other bias
0% 25% 50% 75% 100%
Low risk of bias Unclear risk of bias High risk of bias
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Drake 1998 + + + + + + + - +
Garcia 1988 ? ? + + + + + ? +
Khan 2010 + ? + + - - + ? +
Liniger 2003 - ? + + + + ? - +
Pollack 1999 ? ? + + + + + ? +
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Figure 3.   (Continued)
Liniger 2003 - ? + + + + ? - +
Pollack 1999 ? ? + + + + + ? +




Two studies described an adequate random sequence generation
(low risk of bias: Drake 1998; Khan 2010). Two studies provided
insu@icient information to make a judgement (unclear risk of
bias: Garcia 1988; Pollack 1999) and two studies performed
inadequate methods for randomisation or included a non-
randomised component for participants' allocation (high risk of
bias: Liniger 2003; Warf 2005). Only one study adequately described
concealment of allocation (low risk of bias: Drake 1998), while the
rest of the studies provided insu@icient information to make a
judgement (unclear risk of bias).
Blinding
Subjective outcomes: treatment failure, adverse events, quality
of life
Considering that the interventions were visibly di@erent between
groups, none of the studies were blinded (high risk of performance
bias).  However, one study had an independent assessment of
outcomes by a blind adjudication committee (low risk of detection
bias: Drake 1998).
Objective outcomes: mortality, head circumference, ventricular
size
We judged separately objective outcomes, for which we considered
these studies to be at a low risk of performance and detection bias.
Incomplete outcome data
All outcomes
Outcome data was available for all participants in four studies (low
risk of bias: Drake 1998; Garcia 1988; Khan 2010; Pollack 1999).
There was no information on missing outcome data in one study
(unclear risk of bias: Liniger 2003). One study excluded participants
that were lost to follow-up from the analysis and there was an
unbalanced attrition (high risk of bias: Warf 2005).
Selective reporting
All outcomes
Risk of bias was unclear for most studies as there were no
study protocols (Garcia 1988; Khan 2010; Pollack 1999; Warf
2005). However, two studies failed to report predefined outcomes
or time points and presented outcome data (e.g. mortality) globally
but not by each treatment group (Drake 1998; Liniger 2003); these
studies were judged as being at high risk of bias.
Other potential sources of bias
All outcomes
No other sources of bias were detected.
E3ects of interventions
See: Summary of findings 1 Standard valve compared to
anti-syphon valve for hydrocephalus; Summary of findings 2
Comparison between di@erent types of standard valves; Summary
of findings 3 Standard valve compared to self-adjusting CSF
flow-regulating valve  for hydrocephalus; Summary of findings 4
External di@erential programmable pressure valve compared to
non-programmable valves
1. Standard valve versus anti-siphon valve
Three studies with 296 randomised participants were included
under this comparison (Drake 1998; Khan 2010; Liniger 2003).
One study compared standard valves versus a group of valves
including the anti-siphon  valve for which no disaggregated data
was available, therefore this study is described separately (Pollack
1999). Drake 1998 compared a standard valve versus a Delta anti-
siphon valve; Khan 2010 compared a group of standard  valves
(Chabbra and Cederain) versus a Vygon anti-siphon valve; Liniger
2003 compared a standard (Pudenz mid-pressure) valve versus a
Delta anti-syphon valve. See Summary of findings 1.
1.1. Treatment failure
We are uncertain about the incidence of treatment failure in
participants with standard valve compared to anti-siphon valves:
• Drake 1998 reported this outcome in 229 participants. The
authors stated that "there were no di@erences among the three
shunt valve groups, either by log-rank tests for equality of
the three curves (log-rank = 2.90, P = 0.24)" [the third arm
included a Orbis-Sigma valve]. The incidence of treatment
failure at two years follow-up was: 42.98% in the standard valve
group (39 shunt obstruction, 3 over-drainage, 7 shunt infection)
and 48.69% in the Delta anti-syphon valve group (38 shunt
obstruction, 9 over-drainage, 9 shunt infection).
• Khan 2010 reported this outcome in 40 participants. The
incidence of treatment failure at three to six months follow-up
included: four cases of shunt obstruction and four cases of shunt
infection and no cases of over-drainage with the Vygon anti-
siphon valve; and three cases of shunt obstruction, three cases
of shunt infection and two cases of shunt over-drainage with
the standard valve (reported P values were 1.00, 1.00 and 0.49
respectively for these comparisons).
• Liniger 2003 reported this outcome in 27 participants. The
incidence of emergency treatment failure at nine years of clinical
follow-up  included six (55%) of 11 participants in the group
of shunt revision with the standard  and eight (50%) of 16
participants in the group of shunt revision with the Delta anti-
siphon valve.  When elective revisions were included in the
analysis, 63% of participants su@ered treatment failure (no
disaggregated data by each type of intervention was available).
In the early follow-up (six months from shunt insertion), 30%
of participants with standard valves and 14% with anti-siphon
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valves  developed a "slit ventricle" (n =  24 participants) and
64% of participants with  standard valves  and 38% with  anti-
syphon valves developed slit ventricle in the late follow-up (at
six years of age, n= 27 participants). The authors also reported
that 9% of participants with standard valves  and 6.25% of
participants with anti-syphon valves developed a "slit ventricle
syndrome", defined as slit ventricles in radiological studies with
recurrent clinical signs of intracranial hypertension, namely
severe headaches and emesis, and slow or no refill of the valve.
The certainty of the evidence is very low due to concerns about
bias (downgraded two levels due to high or unclear risk of bias
in multiple domains of the included studies) and imprecision
(downgraded one level due to few participants and events in each
study).
1.2. Adverse events
The incidence of adverse events was reported by one study
with 229 participants (Drake 1998). The incidence of adverse
events may be similar in those with standard valves  and anti-
siphon valves. With the Delta anti-siphon valve, 0% of participants
developed an intracranial haemorrhage, 0% developed a new or
increased neurological deficit, 0% developed a neck injury, 0.9%
developed a chest injury, 0% developed an abdominal injury,
0.9% developed an inadvertent skin perforation along the shunt
tract, 1.7% developed a wound dehiscence, 2.9% developed  a
postoperative subcutaneous fluid collection, and 0% developed a
transient wound cerebrospinal fluid leak, while with the standard
valve 0.9% of participants developed an intracranial haemorrhage,
0% developed a new or increased neurological deficit, 0.9%
developed a neck injury, 0.9% developed a chest injury, 0%
developed an abdominal injury, 0% developed an inadvertent
skin perforation along the shunt tract, 1.8% developed a wound
dehiscence, 1.9% developed a  postoperative subcutaneous fluid
collection, and 0.9% developed a transient wound cerebrospinal
fluid leak.
The other studies did not report adverse events beyond those
reported under "treatment failure" (Khan 2010; Liniger 2003).
The certainty of the evidence is low due to concerns about bias and
imprecision.
1.3. Mortality
Only one study with 229 participants reported this outcome under
this comparison (Drake 1998). Mortality may be similar in those
with standard valves and anti-siphon valves.
In the postoperative period,  0.9% of participants died with the
Delta anti-siphon valve. No participant with the standard valve died
in this period (risk di@erence [RD] 0.01%, 95% CI -0.02% to 0.03%,
Analysis 1.1).
Beyond the early postoperative period, the authors  stated that
"nine patients died, four as a result of a progression of neoplastic
disease and the others as a result of hyponatraemia, sepsis,
progressive respiratory disease, gastroenteritis, or sudden infant
death", but no disaggregated data by group was available. 
The certainty of the evidence is low due to concerns about bias and
imprecision.
1.4. Quality of life
None of the included studies reported this outcome.
1.5. Ventricular size reduction
Ventricular size may be similar in those with standard valves and
anti-syphon valves.
Khan 2010 reported the Modified Evan’s index (MEI) at six-month
follow-up and stated "the decrease in mean MEI from 0 month
to three months was more in the non-anti-siphon group than the
anti-siphon group but it was statistically not significant" (data were
presented graphically, P values not available) (Khan 2010).
Liniger 2003 reported that ventricular surface measured at six years
follow-up was similar with both valves: standard valve 8.5 cm2 (95%
CI, 4.2 - 12,7) and anti-siphon valve 5.8 cm2(95% CI, 4.0 - 7.5) P value
= 0.45.
The certainty of the evidence is low due to concerns about bias and
imprecision.
1.6. Head circumference
Two studies with 67 participants reported this outcome (Khan 2010;
Liniger 2003). Head circumference may be similar in those with
standard valves and those with anti-syphon valves. In one study at
six months follow-up, the mean occipital head circumference was
35.86 cm with the standard valve and 36.6 cm with the anti-siphon
valve  (no standard deviation data were available) (Khan 2010).
In the other study, the median (range) head circumference  at a
corrected age of 7 years was 51 cm (48-56) with the standard valve
and 52 cm (46-55) with the anti-siphon valve (Liniger 2003).
The certainty of the evidence is low due to concerns about bias and
imprecision.       
2. Comparison between di3erent types of standard valves
Two studies with 174 randomised participants were included under
this comparison (Garcia 1988; Warf 2005). Garcia 1988 compared
a standard Hakim ball-in-cone and spring valve versus a standard
distal cleO valve; and  Warf 2005  compared a standard  Chhabra
valve versus a standard Codman-Hakim micro precision valve. See
Summary of findings 2.
2.1. Treatment failure
We are uncertain about the incidence of treatment failure in
participants with di@erent types of standard valves:
• Garcia 1988  reported this outcome in 84 participants. A total
of 26 treatment failures occurred (30.9% global incidence
of treatment failure), four with the  standard distal cleO
valve  and eight  with the  standard Hakim ball-in-cone and
spring valve  during the early postoperative period (30
days), while five participants with the  standard distal cleO
valve and nine with the standard Hakim ball-in-cone and spring
valve  developed treatment failure  during the late follow-up
period (early postoperative period: RR 0.41, 95% CI 0.13 to 1.27,
Analysis 2.1). Treatment failure with the standard distal cleO
valve was due to ventricular obstruction in 22% of participants
(n = 2), peritoneal obstruction in 56% of participants (n =
5),  hyperfunction in 0% of participants (n = 0), inadequate
pressure in 11% of participants (n = 1) and not determined in
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11% of participants (n = 1).   With the  standard Hakim ball-in-
cone and spring valve, treatment failure was due to ventricular
obstruction in 18% of participants (n = 3), peritoneal obstruction
in 24% of participants (n = 4),  hyperfunction in 12% of
participants (n = 2), inadequate pressure in 0% of participants (n
= 0), and not determined in 46% of participants (n = 8).
• Warf 2005  reported this outcome in 90 participants. At 12
months follow-up, 21 participants with the Chabbra valve and
15 participants with the Codman-Hakim micro precision
valve  su@ered complications (RR 1.17, 95% CI 0.72 to 1.92,
Analysis 2.1). Seven percent (n = 3) of participants with
the Chhabra valve  developed valve malfunction,  9.3% (n =
4) developed infections, 2.3% (n = 1) developed proximal
obstruction, 2.3% (n = 1) developed distal obstruction and 9.7%
(n = 3) developed migration. With the  Codman-Hakim micro
precision valve, 0% of participants (n = 0) developed valve
malfunction,  11% (n = 4) developed infections, 2.7% (n = 1)
developed proximal obstruction, 0% (n = 0) developed distal
obstruction and 8.3% (n = 3) developed migration.
The certainty of the evidence is very low due to concerns about
bias (downgraded two levels due to high or unclear risk of bias
in multiple domains of the included studies) and imprecision
(downgraded one level due to few participants and events in each
study).
2.2. Adverse events
None of the included studies reported this outcome beyond those
included under "treatment failure".
2.3. Mortality
We are uncertain about the e@ects of di@erent types of standard
valves on mortality:
• Warf 2005 reported that in the early postoperative period (one-
month follow-up), 2% (n = 1) participant died with the Chhabra
valve, while no participant with the Codman-Hakim micro
precision valve  died in this period (RD 0.02%, 95% CI -0.04%
to 0.09%, Analysis 2.2). Beyond the early postoperative period
(12 months follow-up), 14% (n = 6) of participants died with the
Chhabra valve while 17% (n = 6) of participants died with the
Codman-Hakim micro precision valve (RD -0.03%, 95% CI -0.19%
to 0.13%, Analysis 2.2).
• Garcia 1988 reported that four participants with the standard
distal cleO valve  and no participant with the standard Hakim
ball-in-cone and spring valve  died in the early postoperative
period (RD 0.09%, 95% CI -0.00% to 0.18%, Analysis 2.2). The
cause of death with the first valve was pneumonia and sepsis
(two cases), ependymitis (one case) and brain stem compression
(one case).
The certainty of evidence is very low due to concerns about risk of
bias and imprecision (few events).
None of the included studies reported the e@ects of these
interventions on quality of life, ventricular size reduction and head
circumference.
3.  Standard valve versus self-adjusting CSF flow-
regulating valve
One study with 229 randomised participants addressed this
comparison (Drake 1998). This study compared a standard valve
with the Orbis-Sigma self-adjusting CSF flow-regulating  valve
(Cordis). See Summary of findings 3.
3.1. Treatment failure
Drake 1998  reported this outcome in 229 participants. The
incidence of treatment failure may be similar in those with the
standard valve  and the constant flow valve. The incidence of
treatment failure at two years follow-up was 42.98% with the
standard valve (39 shunt obstruction, 3 over-drainage, 7 shunt
infection, 0  loculated compartments) and 39.13% with the Orbis-
Sigma valve  (31  shunt obstruction, 0  over-drainage, 12  shunt
infection, 2 loculated compartments) (RR 1.08, 95% CI 0.79 to 1.47,
Analysis 3.1).
The certainty  of the evidence is low  due to concerns about
bias (high or unclear risk of bias in multiple domains of the included
study) and imprecision (few events leading to a wide confidence
interval).
3.2. Adverse events
Drake 1998  reported postoperative complications. The incidence
of adverse events may be similar in those with the standard valve
and those with the self-adjusting CSF flow-regulating valve. With
the  standard valve, 0.9% of participants developed  intracranial
haemorrhage, 0% developed new or increased neurological deficit,
0.9% developed neck injury, 0.9% developed chest injury, 0%
developed abdominal injury, 0% developed inadvertent skin
perforation along shunt tract, 1.8% developed wound dehiscence,
1.9% developed  postoperative subcutaneous fluid collection
and 0.9% developed transient wound cerebrospinal fluid leak; with
the Orbis-Sigma self-adjusting CSF flow-regulating  valve,  0% of
participants developed  intracranial haemorrhage, 0% developed
new or increased neurological deficit, 0% developed neck injury,
0.9% developed chest injury, 0% developed abdominal injury,
0% developed inadvertent skin perforation along shunt tract,
0% developed wound dehiscence, 7.2% developed postoperative
subcutaneous fluid collection and  0.9% developed transient
wound cerebrospinal fluid leak.
The certainty  of the evidence is low due to concerns about bias
(high or unclear risk of bias in multiple domains of the included
study) and imprecision.
3.3. Mortality
Drake 1998  reported no deaths with either valve in the
postoperative period.  Beyond the early postoperative period,
the authors  stated that "nine  patients died, four as a result
of progression of neoplastic disease and the others as a
result of hyponatraemia, sepsis, progressive respiratory disease,
gastroenteritis, or sudden infant death", but no disaggregated data
by each type of intervention were available. 
The certainty of the evidence is low due to concerns about bias and
imprecision.
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None of the included studies reported the e@ects of these
interventions on quality of life, ventricular size reduction and head
circumference.
4. External di3erential programmable pressure valve versus
non-programmable valve
One study with 377 randomised participants addressed this
comparison (Pollack 1999). The study compared a Codman-Hakim
programmable valve system versus any other non-programmable
fixed pressure valves of surgeon's choice available on the market
(including Delta anti-syphon valves, Orbis-Sigma valves and other
Medtronic PS Medical or other Codman/Johnson & Johnson valves)
with no disaggregated data available within this  group.  See
Summary of findings 4.
4.1. Treatment failure
Pollack 1999  reported this outcome in 377 participants.  The
incidence of treatment failure may be similar in those with
the programmable valve and the other non-programmable types
of valves. In the two years' follow-up, 52% (n = 100) of participants
with the programmable valve and 52% (n = 96) of participants
with the other non-programmable fixed pressure valves developed
treatment failure (RR 1.02, 95% CI 0.84 to 1.24, Analysis 4.1). With
the programmable valve, treatment failure occurred in 52% (n
= 62) of 119 participants who underwent initial shunt insertion
and in 43% (n = 32) of 75 participants who underwent an
existing valve replacement.  With the other non-programmable
fixed pressure valves, treatment failure occurred in 50% (n = 58)
of 116 participants who underwent initial shunt insertion and in
43% (n = 29) of 67 participants who underwent an existing valve
replacement.  Infections requiring explantation was developed in
10.8% (n = 21) of participants with the programmable valve and in
8.7% (n = 16) participants with the other non-programmable fixed
pressure valves.
The certainty of the evidence is moderate due to concerns about
bias.
4.2. Adverse events
The incidence of adverse events may be similar in those with
the programmable valve and the other non-programmable types
of valves.
Pollack 1999 reported subdural haematomas or hygromas in 6.19%
(n = 12) of participants with the programmable valve  and in
6.01%(n = 11) of participants with the other non-programmable
fixed pressure valves (RR 0.97, 95% CI 0.44 to 2.15, Analysis 4.2). The
authors stated that "the majority of other complications assessed
as a part of the study (haemorrhage, malabsorption, catheter
perforation, etc.) were extremely uncommon and were reported in
1% or less of either the experimental or control groups."
The certainty of the evidence is low due to concerns about bias and
imprecision.
Ventricular size reduction may be similar in those with the
programmable valve  and the other non-programmable types of
valves (low certainty of evidence). The included study did not report
the e@ects of these interventions on mortality, quality of life and
head circumference.
D I S C U S S I O N
Summary of main results
We included six studies with 962 participants assessing the e@ects
of standard valves compared to anti-siphon valves, other  types
of standard valves, self-adjusting CSF flow-regulating  valves and
external di@erential  programmable pressure valves versus non-
programmable valves.  The certainty of the evidence for most
comparisons was low to very low.
1. Standard valve versus anti-siphon valve
Three studies with 296 randomised participants were included
under this comparison. We are uncertain about the incidence
of treatment failure in participants with standard valve and
anti-siphon valves (very low certainty of the evidence). The
incidence of adverse events may be similar in those with standard
valves  and  anti-siphon valves (low certainty of the evidence).
Mortality may be similar in those with standard valves and anti-
siphon valves (low certainty of the evidence). Ventricular size
and head circumference may be similar in those with  standard
valves  and  anti-siphon  valves (low certainty of the evidence).
None of the included studies reported on the quality of life of
participants.
2. Comparison between di3erent types of standard valves
Two studies with 174 randomised participants were included
under this comparison We are uncertain about the incidence of
treatment failure in participants with di@erent types of standard
valves (very low certainty of the evidence). None of the included
studies reported adverse events beyond those included under
"treatment failure". We are uncertain about the e@ects of di@erent
types of standard valves on mortality (very low certainty of the
evidence). The included studies did not report the e@ects of these
interventions on quality of life, ventricular size reduction or head
circumference.
3. Standard valve versus self-adjusting CSF flow-regulating
valve
One study with 229 randomised participants addressed this
comparison. The incidence of treatment failure may be similar
in those with the standard valve and the self-adjusting CSF flow-
regulating valve  (low certainty of the evidence). The incidence of
adverse events may be similar in those with the standard valve
and those with the self-adjusting CSF flow-regulating valve  (low
certainty of the evidence). The included study reported no deaths
in either group in the postoperative period. Beyond the early
postoperative period, the authors stated that nine patients died
(no disaggregated data for each type of intervention was available,
low certainty of the evidence). The included studies did not report
the e@ects of these interventions on quality of life, ventricular size
reduction or head circumference.
4. External di3erential programmable pressure
valve versus non-programmable valve
One study with 377 randomised participants addressed this
comparison. The incidence of treatment failure may be similar
in those with  programmable valves and the other types of non-
programmable valves (low certainty of the evidence). The incidence
of adverse events may be similar in those with programmable
valves  and the other types of non-programmable valves  (low
Ventriculo-peritoneal shunting devices for hydrocephalus (Review)









Cochrane Database of Systematic Reviews
certainty of the evidence). The included study did not report
the e@ect of these interventions on mortality, quality of life or
head circumference. Ventricular size reduction may be similar in
those with  programmable valves  and the other types of non-
programmable valves (low certainty of the evidence).
Overall completeness and applicability of evidence
Participants with the most frequent types of hydrocephalus
were included across the di@erent included studies.  These were
conducted mainly in children and infants, similar to those that
can be found in clinical practice. Only one study was conducted in
adults, so this population might not be well represented.
We did not find studies assessing some of the planned
interventions. The use of more advanced technology in valves, such
as those with anti-gravitational mechanisms plus the possibility
of external regulation, have yet to be tested versus those
of fixed pressure or anti-siphon devices. Furthermore, current
interventions for hydrocephalus might be considered di@erent
from those in the included studies, due to the emergence of more
complex devices with anti-siphon systems combined with di@erent
degrees of fixed pressures or external regulation. Additionally,
when the included studies were conducted, endoscopic third-
ventriculostomy was not available for the treatment of
hydrocephalus, probably because of the lack of training among
neurosurgeons and the lack of endoscopy instruments, making this
intervention not available worldwide. Nowadays, it has become a
viable option when valves are not available or when the etiology
of hydrocephalus is associated with higher success with  this
procedure.
Not all the outcomes of interest for this review have been
reported in the included studies. We also identified heterogeneity
in outcome definition among studies. In some studies, valve
setting was modified by each surgeon's discretion and patient
outcomes related to those modifications (i.e. ventricle size) were
not independently reported, not allowing a proper assessment.
However, the measurement of the outcomes nowadays remains
similar, with a similar degree of subjectivity. Nevertheless, by
recent improvements of imaging, ultrasound, CT scan and MRI,
there is a possibility of taking uniform and more objective
measures that could be used to establish uniform criteria on
outcome definition. Similarily, neuropsychological studies have
been developed recently and can adequately estimate the quality
of life of patients treated for hydrocephalus. It is important to
highlight that some adverse events may be more dependent on the
shunting procedure than the type of device itself (e.g. slit ventricle,
subdural collection, infection, etc.).
Quality of the evidence
The overall quality of the evidence was low to very low. All studies
had high risk of bias, mainly due to lack of blinding leading to
possible performance bias influencing the main outcomes. Even for
outcomes that might be una@ected by blinding, we found concerns
regarding the randomisation and allocation process, missing data
and selective reporting. Some studies were very small and had few
events that led to important imprecision. We were unable to assess
publication bias due to the scarcity of studies per outcome.
Potential biases in the review process
We rearranged and redefined the outcomes to maximise the
use of available data. We took precautions to avoid bias in this
process by documenting all changes in the section Di@erences
between protocol and review. We also initially planned to conduct
meta-analysis but the quality of the reports was so low and
sparse that we opted for Synthesis Without Meta-analysis (SWiM),
which is a new method available in the Cochrane Handbook.
We were unable to conduct prespecified sensitivity and subgroup
analyses. We attempted to minimise publication bias in the review
by searching multiple databases including trial registers and
conference proceedings.
Agreements and disagreements with other studies or
reviews
We identified nine systematic reviews or health technology
assessments. Four reviews did not provide comparative
e@ectiveness data: three reviews included only descriptive data
from large case series (Ito 2012) or a mix of randomised trials
and observational studies (Wong 2012), one health technology
assessment (ASERNIP-S 2014) provided descriptive data from case
series of a gravitational valve, and one review (Del Bigio 1998)
summarised data from in vitro studies.
One review (Baird 2014) incorporated most of the studies in our
review and a series of observational studies. This review found a
similar incidence of shunt failure across di@erent types of valves
including  programmable valves and anti-siphon valves. While
some observational studies indicated that  programmable valves
(Strata and Codman-Hakim) may have a greater incidence of shunt
failure when compared to other valves, these results were highly
inconsistent (Baird 2014).
Another review (Li 2017) included three randomised studies and
eight observational studies. Two randomised studies included
patients with normal pressure hydrocephalus. This review found
no di@erence in mortality or complications in programmable
valves versus non-programmable valves. Based on data from
observational studies at high risk of bias, a reduced incidence
of shunt revision rates was observed with programmable valves.
Another review found similar results (Rasul 2012).
A review team published two systematic reviews (Xu 2013; Xu
2013a). These reviews included randomised controlled trials and
observational studies that were pooled in meta-analysis and
indicated that there were fewer complications and revision rates
with programmable valves when compared to non-programmable
valves. However, the results from the two versions of the review
di@ered substantially. Furthermore, these results were primarily
driven by observational studies.
This summary suggests that a few reviews found di@erent results
from ours, but this was mostly driven by observational studies.
Furthermore, none of the mentioned reviews were of high quality
and none of them incorporated GRADE methods in the assessment
of the certainty of the evidence.
Ventriculo-peritoneal shunting devices for hydrocephalus (Review)









Cochrane Database of Systematic Reviews
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Standard shunt valves for hydrocephalus compared to anti-siphon
or self-adjusting CSF flow-regulating valves may cause little to no
di@erence on the main outcomes of this review; however, we are
very uncertain due to the low to very low quality of evidence.
Similarly, di@erent types of standard valves and programmable
versus non-programmable valves may be associated with similar
outcomes. Nevertheless, this review did not include valves with the
latest technology.
Implications for research
High-powered RCTs are needed, especially those that consider the
latest technology including those that combine di@erent degrees of
fixed pressures or those with externally-regulated pressure with the
addition of anti-siphon or antigravitational devices. These studies
should consider major outcomes for all stakeholders like patients,
their families, physicians, surgeons, funders and policy-makers.
The cost associated with the procedure, both direct and indirect,
should also be considered. There is also a need for researchers
to establish standardised  outcome  definitions and timings for
their measurements, including newer, more objective and reliable
assessment methods.  
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: parallel-group randomised trial
Study dates: October 1 1993 to October 31 1995
Setting: inpatient, multicentre, international
Country: Canada, United States, France
Participants Inclusion criteria:
Patients between birth and 18 years of age, newly diagnosed hydrocephalus with documented ven-
triculomegaly in CT, MRI or ultrasonographic image scans and requiring a first ventriculo-peritoneal
CSF shunt insertion.
Exclusion criteria:
1- previous indwelling CSF shunt (patients with subcutaneous reservoirs for aspiration or ventricular
catheters draining externally or to the subcutaneous scalp were eligible);
2- active abdominal or CSF infection;
3- diffuse spread of tumour in the subarachnoid space;
4- marked prematurity with skin at risk for erosion from shunt hardware;
5- systemic disorders precluding shunt insertion;
6- septated loculations within the ventricular system requiring more than one shunt;.
7- Dandy Walker malformation;
8- arachnoid cyst as a cause of hydrocephalus;
9- inability to be monitored for 1 year baseline.
Sample size: 344 participants randomised
Group 1: Delta valve 115
Group 2: Standard valve 114 
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Group 3: Orbis-Sigma valve 115 
Age (years):
Group 1: Delta valve: mean 1.83 years, median 0.2 years
Group 2: Standard valve: mean 1.65 years; median 0.21 years
Group 3: Orbis-Sigma valve: mean 1.56 years; median 0.4 years
Sex (M/F):
Group 1: Delta valve 64/51
Group 2: Standard valve 70/44
Group 3: Orbis-Sigma valve 57/58
Hydrocephalus cause
Group 1: Delta valve: intraventricular haemorrhage 19.1%,  myelomeningocele 24.3%, tumour 8.7%,
aqueduct stenosis 7.8%, CSF infection 6.1%, head injury 2.6%, two or more causes 9.6%, other 9.6%,
unknown 12.2%
Group 2: Standard valve: intraventricular haemorrhage  25.9%,  myelomeningocele 24.1%, tumour
8.0%, aqueduct stenosis 8.0%, CSF infection 4.5%, head injury 1.8%, two or more causes 6.3%, other
11.6%, unknown 9.8%
Group 3 Orbis-Sigma valve: intraventricular haemorrhage  28.1%,  myelomeningocele 15.8%, tumour
10.5%, aqueduct stenosis 5.3%, CSF infection 5.3%, head injury 0.0%, two or more causes 10.5%, other
13.2%, unknown 11.4%
Previous surgery:
Group 1 Delta valve: subcutaneous reservoir 6.1%, ventricular drain 8.0%
Group 2 Standard valve: subcutaneous reservoir 6.1%, ventricular drain 11.9%
Group 3 Orbis-Sigma valve: subcutaneous reservoir 7.1%, ventricular drain 18.0%
Interventions Group 1 (n = 115): Delta valve (Medtronic PS Medical): a standard diaphragm valve with an addition-
al anti-syphon device that consists of paired flexible diaphragms, which narrow an orifice as the shunt
pressure becomes negative
Group 2 (n = 114): Standard (conventional) valve 
Group 3 (n = 115): Cordis Orbis-Sigma valve. This is a flow-regulation valve with a flexible diaphragm
which moves along a piston of variable diameter. It operates through three stages, so that the pressure
curve is sigmoid in shape which limits flow by progressively narrowing the flow orifice with increasing
pressure, as a pressure-sensitive ring moves along a variable-diameter rod with a single opening pres-
sure of approximately 5 cm H2O.
Co-interventions: The details of the surgical technics and postoperative care were established accord-
ing to the discretion of the surgeon and were recorded (including the prophylactic use of antibiotics,
hair removal, the site of hardware insertion, the use of technical aids such as ventriculoscopes, hard-
ware configurations, opening pressure designations for the standard and Delta valves, and postopera-
tive head elevation or compressive dressings). Suggestions from the manufacturers for insertion tech-
niques were solicited at the beginning of the trial and were distributed to all participating centres.
Outcomes Treatment failure 
How measured: defined as shunt malfunction due to shunt obstruction, shunt over-drainage, loculated
ventricles, or shunt infection. Each of these end points were defined by specific criteria in the trial pro-
tocol (see below). An adjudication committee, blinded to the treatment group, reviewed each patient´s
imaging studies, operative notes and hospital discharge summary when a primary end point was re-
ported.
Drake 1998  (Continued)
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Time points measured:  clinical evaluation at 3 months, 1 year, and yearly until the end of the study
Time points reported: complete follow-up
Treatment failure [shunt obstruction]
Definition: 
1. If a patient has at least one symptom or sign and at least one positive ancillary test
Symptoms: headache, nausea, vomiting, decreased level of consciousness, irritability, decreased
school performance, loss of developmental milestones
Signs: papilledema, bulging fontanelle, nuchal rigidity, 6th nerve(s) paresis, loss of upward gaze, new
seizures (or increased seizure frequency), increasing head circumference, fluid tracking along the shunt
tubing, umbilication of the shunt reservoir, inability to depress the shunt reservoir. Fluid accumulation
around the burr hole site in the early weeks following surgery will not be considered indicative of shunt
failure unless it is extreme and progressive or results in leakage of CSF through the wound. Small fluid
collections are common and normally resolve spontaneously.
Ancillary tests:
(a) CT scan, ultrasound, or MRI scan showing enlarged ventricles compared to the 3-month study or
ventricles that have failed to decrease in size compared to the preoperative study (normalisation of
ventricle size is not a mandatory criterion for shunt function)
(b) Disruption or migration of the shunt system on plain radiographs
(c) Radionucleotide or iodinated contrast study showing shunt obstruction
(d) ICP monitoring showing persistent elevation of pressure with or without plateau waves
(e) Shunt tap in which fluid cannot be aspirated or high pressure is recorded or symptoms/signs of
shunt obstruction are relieved
2. When there are no symptoms or signs of shunt obstruction but the ventricles are increased in size,
shunt obstruction is said to have occurred if there is no clinical or radiographic suggestion that atrophy
is the cause of the ventricular enlargement.
3. A CSF leak that does not resolve and which requires a shunt revision
4. In the rare event of an emergent shunt revision without any ancillary tests, or revision prior to the 3-
month follow-up scan, obstruction will be judged to be present or absent using clinical information and
the operative findings (by the Monitoring/Adjudication Committee)
Time points measured:  clinical evaluation at 3 months, 1 year, and yearly until the end of the study
Time points reported: complete follow-up
Treatment failure [shunt over-drainage]
Definition:  in the presence of (a) subdural fluid collections - large subdural fluid collections associat-
ed with brain compression or symptoms and signs otherwise indicative of shunt obstruction; or (b)
slit ventricle syndrome - smaller than normal ventricles associated with postural headache, chronic
headache, intermittent headache of an incapacitating nature and documentation of one of the follow-
ing: (1) transient enlargement of the ventricles as seen on imaging; (2) extreme negative pressure with
associated headache in the upright position; (3) sustained elevations of pressure above normal associ-
ated with headache
Time points measured:  clinical evaluation at 3 months, 1 year, and yearly until the end of the study
Time points reported: complete follow-up
Treatment failure [loculated ventricles]
Definition: The presence of a loculated portion of a ventricular system that is enlarged above normal
and compressing surrounding brain and that requires reoperation
Time points measured:  clinical evaluation at 3 months, 1 year, and yearly until the end of the study
Drake 1998  (Continued)
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Time points reported: complete follow-up
Treatment failure [shunt infection]
Definition:  
1. In the presence of purulent discharge through the wound or erosion of the shunt material through
the skin
2. In the presence of one of the following symptoms or signs with at least one of the following ancillary
tests
Symptoms and signs: fever, meningismus, wound erythema, abdominal pain and/or distention, ab-
dominal mass or peritonitis
Ancillary tests: culture or identification of organisms on Gram stain of CSF taken from shunt lumen or
abdominal fluid collection, if present, withdrawn under sterile conditions or from purulent material
around the shunt
Time points measured:  clinical evaluation at 3 months, 1 year, and yearly until the end of the study
Time points reported: complete follow-up
Adverse events [surgical complications]
How measured: not specified. The following events were included in this outcome (obtained from the
Hospital Discharge Form): transient CSF leak, intracranial haemorrhage, new or increased neurologi-
cal deficit, neck injury, chest injury, abdominal injury, inadvertent skin perforation along shunt tract,
wound dehiscence, postoperative subcutaneous fluid collection, perioperative death, and "other"
complications. 
Time points measured: time of hospital discharge
Time points reported: time of hospital discharge
Mortality for all causes
How measured: not specified. Cause of death was recorded on a death form and classified as probably
related to shunt malfunction; neurologic, but probably not related to the shunt malfunction; or non-
neurological.
Time points measured: complete follow-up
Time points reported: complete follow-up
Quality of life: not reported
Ventricular size reduction: not reported
Head circumference: not reported
Funding sources Medtronic PS Medical (Goleta, CA), Cordis Corp (Miami FL), British Columbia Health Research Foun-
dation and The Science Council of British Columbia (Burnaby Canada), Mr. and Mrs. PA Woodward´s
Foundation (Vancouver Canada) British Columbia´s Children´s Hospital Telethon Clinical Investigative
Initiatives (Vancouver, Canada) British Columbia´s Medical Services Foundation (Vancouver, Canada)
Spina Bifida Association of Canada (Winnipeg, Canada) and Spina Bifida Association of British Colum-
bia (Surrey, Canada)
Declarations of interest Not reported
Notes 1) Standard differential pressure valves can be classified into four categories: silicone rubber slit valves,
silicon rubber mitre valves, metallic spring ball valves. Below a  threshold difference in pressure across
the valve, it remains closed, and above the threshold difference in pressure, it opens (the opening pres-
sure). Conventional valves are supplied usually as low, medium and high pressure. Although there are
Drake 1998  (Continued)
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no uniform standards for these designations, typically their pressure differentials are 5, 10 and 15 mm
H2O, respectively. Despite the variations in the standard valve design, the pressure/flow characteristics
are very similar. 
2) Assessment at 3 months, 1 year and yearly until the end of the study were performed by the attend-
ing neurosurgeon during an outpatient hospital visit by the patient, using a specific form. Follow-up
included imaging studies at 3 months and thereafter according to the surgeons' individual practices.
A 12-month scan was encouraged if possible. A completed telephone follow-up form was required at
months 18 and 30. A minimum follow-up of 1 year was required.
The details of the surgical techniques and postoperative care were established according to the dis-
cretion of the surgeon, including the prophylactic use of antibiotics, hair removal, the site of hardware
insertion, the use of technical aids such as ventriculoscopes, hardware configurations, opening pres-
sure designations for the standard and Delta valves, and postoperative head elevation or compressive
dressings. Suggestions from the manufacturers for insertion techniques were solicited at the beginning
of the trial and were distributed to all participating centres.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk “Patients were stratified by centre and by age (less than or more than 6 mo),










events, quality of life
High risk Study personnel were aware of the type of valve that the patient received. The
shunts were distinctly different in shape, can be easily palpated through the







Low risk No information about blinding available. Outcomes were likely to be unaffect-
ed by blinding.




events, quality of life
Low risk "Determination of outcome will be made by the neurosurgeon in charge of the
care of the child at the time of the malfunction. The outcome will be reviewed
by the adjudication committee, which will be blinded to the type of shunt in
place."  










Low risk Eight patients did not complete the minimum 1-year follow-up period. “8/344
patients did not complete the minimum 1-year follow-up period.”
Drake 1998  (Continued)
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Selective reporting (re-
porting bias)
High risk Some outcomes listed in the protocol were not reported, e.g. change in ven-
tricular size, hospital stay. Data on mortality was not disaggregated by group.





Methods Study design: parallel-group randomised trial
Study dates: study dates not available
Setting: inpatient procedure - outpatient follow-up
Country: Mexico
Participants Inclusion criteria: adult patients with hydrocephalus
Exclusion criteria: not available
Sample size: 84 patients
Age (years):
Group 1 (intervention) mean 43.1
Group 2 (control) mean 43.7
Sex (M/F):
Group 1 57% male; 43% female
Group 2 56% male; 44% female
Relevant participant details (diagnosis):
Neoplasm (8.6% intervention, 15.7% control) - including meningeoma, medulloblastoma and pineal tu-
mours
Inflammatory (60.8% intervention, 42.1% control) - including cysticercosis and nonspecific arachnoidi-
tis
Vascular (13% intervention, 15.7% control) - including subarachnoid haemorrhage and cerebellar in-
farction or haemorrhage
Other (17.3% intervention, 26.3% control) - including traumatic, congenital and normotensive
Interventions Group 1 (n = 46): Biomed distal valve (antireflux). This group received 54 valves. Seven patients received
more than one valve (15 systems due to dilatation or failure).
Group 2 (n = 38): Cordis-Hakim proximal valve (ball in cone). This group received 42 valves. Eight pa-
tients received more than one valve (23 systems due to dilatation or failure).
Co-interventions: all patients received antibiotic prophylaxis (doxycycline and chloramphenicol) and a
computerised tomography before the surgery, at the 7th and 15th and 30th day postoperatively.
Outcomes Treatment failure
How measured: surgical re intervention for changing the shunting device due to obstruction, infection,
or over-drainage G1: 9 valves in 8 patients (14%) G2: 17 valves in 11 patients (46%)
Time points measured:
Garcia 1988 
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G1: 12.7 ± 4.6 months
G2: 9.4 ± 7.3 months.
Time points reported:
G1: 1 to 21 months.
G2: 1 to 36 months
Subgroups: none
Adverse events
How measured: CSF culture (infection) or computerised tomography scan - > also reported under treat-
ment failure.
Time points measured: "early" or "late" (mean follow-up 4 months, range 1-24 months)
Time points reported: idem
Subgroups: none
Mortality
How measured: not specified
Time points measured: complete follow-up (mean follow-up 4 months, range 1-24 months)
Time points reported: complete follow-up (mean follow-up 4 months, range 1-24 months)
Subgroups: none
Quality of life: not reported
Ventricular size reduction: not reported
Head circumference: not reported
Funding sources Not available
Declarations of interest Not available
Notes This study reported a subjective clinical scale: "excellent" (normal function), "good" (few symptoms,
independent in daily life activities), "regular" (greater symptoms, minor impairment in daily activities),
"bad" (major impairment and dependent on continuous care including hospital care).
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Quote: "a prospective randomised study"
No other information available
Allocation concealment
(selection bias)
Unclear risk Quote: "a prospective randomised study"






events, quality of life
High risk No information about blinding available, however personnel was aware of the
type of shunt being placed during the procedure
Garcia 1988  (Continued)
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Low risk No information about blinding available, however personnel was aware of the
type of shunt being placed during the procedure. Outcomes were likely to be
unaffected by blinding.




events, quality of life
High risk No information about blinding available, however personnel was aware of the
type of shunt being placed during the procedure





Low risk No information about blinding available, however personnel was aware of the





Low risk All outcomes: follow-up data was complete for all participants.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’ (no
protocol available)





Methods Study design: parallel-group randomised trial
Study dates: study dates not available
Setting: inpatient procedure - outpatient follow-up
Country: India
Participants Inclusion criteria: participants between 20 days to 8 months, with progressive hydrocephalus with or
without neural tube defect (NTD). The most common cause of hydrocephalus in children without NTD
was aqueductal stenosis.
Exclusion criteria: patients having meningitis, ventriculitis, hydrocephalus secondary to mass lesions,
intraventricular haemorrhage, peritoneal infection or peritoneal adhesions
Sample size: 40 eligible were randomly allocated using random number table. Patients: 26 NTD hydro-
cephalus and 14 without NTD
Age (years):
Group A: Anti-siphon group (20 days to 8 months, mean 3.5)
Group B: Non-antisyphon (25 days to 8 months)
Sex (M/F) Group A: 6 female, 14 male; Group B: 5 female, 15 male
Relevant participant details:
Khan 2010 
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Group A:
Neural tube defect 35%
Low shunt pressure 85%
Medium shunt pressure 15%
Group B:
Neural tube defect 35%
Slow shunt pressure 80%
Medium shunt pressure 20%
Interventions Group A (n = 20): with anti-syphon device (Vygon)
Group B (n = 20): without anti-syphon device (Chhabra and Ceredrain)
Outcomes Treatment failure
How measured: number of participants with shunt block, shunt infection and over-drainage
Time points measured: 3 and 6 months
Time points reported: unclear (possibly 6 months)
Adverse events (morbidity)
How measured: number of participants with shunt block, shunt infection and over-drainage
Time points measured: 3 and 6 months
Time points reported: unclear (possibly 6 months)
Head circumference
How measured: Occipito frontal circumference (OFC)
Time points measured: at discharge, 3 and 6 months postoperative
Time points reported: at discharge, 3 and 6 months postoperative
Ventricular size
How measured: Modified Evan’s index (MEI) assessed by computerised tomography
Time points measured: at discharge, 3 and 6 months postoperative
Time points reported: at discharge, 3 and 6 months postoperative
Mortality for all causes: not reported
Quality of life: not reported
Funding sources Not available
Declarations of interest Not available
Notes No description was made about why surgeons chose different pressures and little information is pro-
vided on the types of valves used.
Contact information: drrizwanahmadkhan@yahoo.co.in (R.A. Khan).
Risk of bias
Bias Authors' judgement Support for judgement
Khan 2010  (Continued)
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Random sequence genera-
tion (selection bias)




Unclear risk No information available. Insufficient information to permit judgement of ‘Low






events, quality of life
High risk No information about blinding available, however blinding was unlikely due to







Low risk No information about blinding available. Outcomes were likely to be unaffect-
ed by blinding.




events, quality of life
High risk No information about blinding available, however blinding was unlikely due to
the visibly different interventions.










Low risk All outcomes: outcome data were available for all participants.
Selective reporting (re-
porting bias)
Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’ (no
protocol available)





Methods Study design: parallel-group quasi-randomised trial
Study dates: start date: 1992 – end date: 1996
Setting: inpatient procedure – outpatient follow-up
Country: Switzerland
Participants Inclusion criteria: 27 patients between 36 days to 6 months, with progressive hydrocephalus with docu-
mented ventriculomegaly by computed CT scan, MRI or ultrasonographic image scans and requiring a
first ventriculoperitoneal CSF shunt insertion
Liniger 2003 
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Exclusion criteria: not available
Sample size: 27 randomised participants
Age:
Group A: median age at surgery in months 3.4 (1 – 5 months)
Group B: median age at surgery in months 2.2 (0 – 4 months)
Sex (M/F): not available
Relevant participant details:
Group A:
• Congenital/acquired hydrocephalus 8/3
• Mean head circumference: 43 cm
• Percentiles 10 > 97.1 = 97
• Ultrasound mean thalamus-occipital horn distance: 42 mm
• Mean with of lateral ventricles: 43
• Mean (range) of IVP: 185 (100-240) mm H2O
• CT/MRI mean age Evan's index 0.46 (0.3-0.6)
• Mean frontal/occipital brain mantle: 15.5/7 mm
Group B:
• Congenital/acquired hydrocephalus 11/3
• Mean head circumference: 41 cm
• Percentiles 10 > 97.1 = 50
• Ultrasound mean thalamus-occipital horn distance: 27
• Mean with of lateral ventricles: 47
• Mean (range) of IVP: 172 (100-260) mm H2O
• CT/MRI mean age Evan's index 0.32 (0.2-0.5)
• Mean frontal/occipital brain mantle: 17/11 mm
Previous Surgery: no
Details of valve selection: not available
Interventions Group A (n = 11): “conventional medium pressure valve” (PS Medical flow control valve, Goleta CA,
medium pressure)
Group B (n = 16): "Anti-siphon valve" (PS Medical Delta, level 1.0, medium-low pressure)
Common indications: Ventriculoperitoneal shunt was implanted on the right or the side of the larger
ventricle.
Outcomes Treatment failure
How measured: defined as the number of patients with revisions and the type of revisions. Shunt revi-
sions were recorded and compared in respect of the valve inserted and in respect of the development
of slit ventricles.
Time points measured: 3 and 6 months
Time points reported: unclear (possibly 6 months)
Adverse events
How measured: Slit Ventricle (SV) were defined according to the radiological impression of slit-like or
collapsed lateral ventricles in CT or MRI scans. Slit Ventricle syndrome was defined as SV with recurrent
Liniger 2003  (Continued)
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clinical signs of intracranial hypertension, namely severe headaches and emesis, and slow or no refill of
the valve.
Time points measured: at 6 months after shunt insertion (early), and at 6 years of age (late)
Time points reported: at 6 months after shunt insertion (early), and at 6 years of age (late)
Ventricular size reduction:
How measured: width of lateral ventricles (CT scan or MRI)
Time points measured: 3 and 6 months
Time points reported: unclear (possibly 6 months)
Head circumference:
How measured: head circumference in cm at a corrected age of 7 years
Time points measured: 3 and 6 months
Time points reported: unclear (possibly 6 months)
Mortality for all causes: not reported
Quality of life: not reported
Funding sources Not available
Declarations of interest Not available
Notes Other outcomes included IVP, psychomotor development (unclear scale of measurement), ultrasound
imaging, mean Evan's index, mean frontal/occipital brain mantle in mm.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Quote: "infants with progressive hydrocephalus were allocated alternately to
either Group A (conventional medium pressure valve) or Group B (Delta valve




Unclear risk No information available. See above. Insufficient information to permit judge-






events, quality of life
High risk No information about blinding available, however blinding was unlikely due to







Low risk No information about blinding available. Outcomes were likely to be unaffect-
ed by blinding.
Blinding of outcome as-
sessment (detection bias)
High risk No information about blinding available, however blinding was unlikely due to
the visibly different interventions.
Liniger 2003  (Continued)
Ventriculo-peritoneal shunting devices for hydrocephalus (Review)









Cochrane Database of Systematic Reviews
Subjective outcomes:
treatment failure, adverse
events, quality of life










Unclear risk No information available. Insufficient information to permit judgement of ‘Low
risk’ or ‘High risk'
Selective reporting (re-
porting bias)
High risk Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’ (no
protocol available). However, outcome data were presented at selective time
points and frequently not disaggregated by group (e.g. shunt failure defined as
elective versus emergency revisions).





Methods Study design: parallel-group randomised trial
Study dates: randomisation June 29, 1993 to December 14, 1995
Setting: inpatient procedure, outpatient follow-up, multicentre, national
Country: United States
Participants Inclusion criteria: patients who required placement of ventriculoperitoneal or ventriculo-atrial shunt
for the treatment of hydrocephalus (first placement or replacement)
Exclusion criteria: patients under treatment with drugs for anticoagulation, coagulopathies, active in-
fection, valve explantation because of infection within the past 3 months, requiring two valves at the
same time, any contraindication for ventriculo-atrial or ventriculo-peritoneal shunting, expected life-
span less than 24 months, and unwillingness or inability to return for required follow-up evaluation at
the investigational site
Sample size: 377 participants randomised
Group 1: Experimental: 194
Group 2: Control: 183
Age (years):
Group 1: Experimental: median 14 (+/- 23)
Group 2: Control: median 12 (+/- 23)
Sex (M/F):
Group 1: 59% male, 41% female
Group 2: 54% male, 46% female
Pollack 1999 
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Diagnosis: 
Group 1: communicating hydrocephalus 59%, non-communicating 41%
Group 2: communicating hydrocephalus 57%, non-communicating 43%
Interventions Group 1: Experimental (n = 194): Codman-Hakim programmable valve system (Codman/Johnson &
Johnson, Raynham, MA) 
Group 2: Control (n = 183): Any non-programmable valve pressure with fixed pressure available on the
market: Delta (Medtronic PS Medical, Goleta Ca): 10%, other Medtronic PS Medical: 57%, other Cod-
man/Johnson & Johnson: 8%, Orbis-Sigma (Cordis, Miami Lakes, FL): 3%, others: 22 %
Co-interventions: The study required that the programmable valve in all patients in whom it had been
placed be reprogrammed after any imaging study because of concern that the valve setting would al-
ter in the magnetic field. Other than this instruction, decisions regarding the programmable valve pres-
sures were leO entirely to the respective investigator's judgement.
Outcomes Primary outcomes
Treatment failure [shunt system failure]:
Definition: a surgical intervention to the original shunt system on-study, for any reason, was considered
a shunt system failure.
Primary outcome measure: survival of the shunt system.
Time points measured: clinical evaluations 1, 3, 6, 12, 18 and 24 months
Time points reported: 24 months
Treatment failure [infection necessitating explantation]:
Definition: not reported
Time points measured: clinical evaluations 1, 3, 6, 12, 18 and 24 months
Time points reported: Not reported (probably 104 weeks)
Adverse events:
Definition: "complications included the following: haemorrhage, malabsorption of CSF, subdural
haematoma/hygroma, neurological deficit, catheter perforation, foreign body reaction, infection, and
“other” complications".
Time points measured: clinical evaluations 1, 3, 6, 12, 18 and 24 months and radiological images at 3,
12 and 24 months
Time points reported: Not reported (probably 104 weeks)
Adverse events [subdural hematoma/hygroma]:
Definition: not reported
Time points measured: clinical evaluations 1, 3, 6, 12, 18 and 24 months
Time points reported: Not reported (probably 104 weeks)
Mortality for all causes:  not reported
Quality of life: not reported
Ventricular size reduction
Definition: ventricle size was reported as big, average, small, or slit, according to qualitative assess-
ment of image studies (computed tomography, MRI, or ultrasound studies).
Pollack 1999  (Continued)
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Time points measured: evaluated at 3, 12 and 24 months with radiological images (ultrasound, CT scan
and MRI)
Time points reported: radiological images at 3, 12 and 24 months
Head circumference: not reported
Funding sources “The authors have no financial involvement with any of the products used in this study.”
Declarations of interest Not available
Notes 1) The Codman-Hakim programmable valve is similar to the original Hakim valve in its ball-cone and
pressure-inducing spring mechanism to achieve differential pressure; however, the pressure setting
can be adjusted by a stepper motor and spiral cam, which are rotated noninvasively using a electro-
magnetic programmer. It can be set while the valve is packaged and sterile, or after implantation. Pres-
sure settings from 30 to 200 mm H2O in increments of 10 mm H2O can be achieved.
2) At a scheduled follow-up visit, an investigator recorded patient status on the following scale: 1) well,
2) symptomatic, relating to hydrocephalus, 3) symptomatic, relating to shunt system, 4) symptomatic,
cause unknown, and 5) symptomatic, unrelated to hydrocephalus or shunt system.
3) Analyses were performed on the first shunt systems for each patient to incorporate the protection
from bias provided by randomisation at study entry.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk “Randomisation was stratified by study site, and within each site randomisa-
tion was stratified further by patient shunt history. Patients with a history of
one or more previous shunts before placement of a study valve were classified
as “replacement” patients. Each of these two groups was randomised sepa-










events, quality of life








Low risk Participants and personnel were not blinded. There was no detail on co-inter-
ventions. Outcomes were unlikely to be affected by blinding.




events, quality of life
High risk Participants and personnel were not blinded.
Pollack 1999  (Continued)
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Low risk 7 patients (2/194  experimental, 5/183 control) were lost to follow-up, 19 died
(11/194 experimental, 8/183 control) before the 24-month follow-up point was




Unclear risk Insufficient information to permit judgement of ‘Low risk’ or ‘High risk’ (no
protocol available)





Methods Study design: parallel-group randomised trial
Study dates: start date: 2001 - end date: 2002
Setting: outpatient, single-centre, national
Country: Uganda
Participants Inclusion criteria: infants with hydrocephalus
Exclusion criteria: not reported
Sample size: 90
Group 1 (n = 47): Chhabra shunt
Age, median (IQR): 8.8 (0.75-84) months
Sex: not reported
Group 2 (n = 43) Codman shunt
Age, median (IQR): 7.4 (0.25-32) months
Sex: not reported
Relevant participant details (diagnosis):
Group 1 (n = 47) Chhabra shunt:
49% of patients had postinfectious hydrocephalus,
14% of patients had hydrocephalus related to myelomeningocele,
37% of patients had non-postinfectious hydrocephalus from other causes (such as congenital).
Group 2 (n = 43) Codman shunt:
64% of patients had postinfectious hydrocephalus,
7% of patients had hydrocephalus related to myelomeningocele,
Warf 2005 
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29% of patients had non-postinfectious hydrocephalus from other causes (such as congenital).
Interventions Group 1 (n = 47): Patients received a Chhabra shunt. The Chhabra shunt (G. Surgiwear Ltd., India) is an
unified shunt system that incorporates a proximal slit-in-spring valve. The Chhabra system is available
in three pressure type models. A medium pressure system allows a flow of 20 mL/hr at a pressure gradi-
ent of 10 cm of water.
Group 2 (n = 43): Patients received a Codman VP shunt. Codman-Hakim Micro Precision Valve (Medos
S. A. [Johnson & Johnson Co.], Switzerland) is a unified shunt using the Hakim Precision Valve. Cod-
man-Hakim Micro Precision Valves are fixed pressure valves and are available in 5 different opening
pressure ranges. The operating pressures of the valve unit have been determined with a flow rate of 10–
25 mL H2O per hour. The valve is classified by its operating pressure with a specified flow rate and not
by its opening and closing pressures.
Co-interventions: "Patients were positioned for right frontal or right occipital shunt placement. An oc-
cipital approach was used with placement of the catheter in the occipital horn, with the exception of
four Chhabra and one Codman shunts, which were placed frontally in the frontal horn. The shunt valve
was flushed and tested to confirm an appropriate closing pressure. The shunt was tunnelled subcuta-
neously between the incisions. A pinpoint of dura was cauterised and punctured after removing bone,
when necessary, and the ventricular catheter was passed. Flow was confirmed, a cerebrospinal fluid
sample was obtained, and the catheter was secured to the valve connector (for the Chhabra) or the in-
tegral reservoir connector (for the Codman) with a 2-0 silk tie. The valve construct was then secured to
the dura or pericranial tissue with a 3-0 silk stitch."
Outcomes Treatment failure
How measured: valve malfunction and infection
Time points measured: 1 week and 3, 6, and 12 months postoperatively
Time points reported: 12 months
Subgroups: none
Adverse events
How measured: infections, obstruction and migration
Time points measured: 1 week and at 3, 6, and 12 months postoperatively
Time points reported: 12 months
Subgroups: none
Mortality for all causes
How measured: not reported
Time points measured: 1 week and at 3, 6, and 12 months postoperatively
Time points reported: 1 and 12 months
Subgroups: none
Quality of life: not reported
Ventricular size reduction: not reported
Head circumference: not reported (only as a baseline characteristic)
Funding sources International Federation for Spina Bifida and Hydrocephalus
CURE International (which funds CURE Children’s Hospital of Uganda)
Warf 2005  (Continued)
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Declarations of interest The author has no financial interest that relates in any way to this report.
Notes The report of the study included a "Group 2" which consisted of 105 consecutive patients in whom on-
ly Chhabra shunts were placed over the course of 9 months. This was prior to March 2002, in which no
Codman shunts were available during this period.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk "Therefore, the type of VP shunt selected for use was random, based on either
coin toss at the time of operation or availability and was in no way influenced
by clinical criteria."
While there was a component of random sequence, the distribution of partici-
pants was also dependent on valve availability.
Allocation concealment
(selection bias)






events, quality of life
High risk No information about blinding available, however personnel was aware of the







Low risk No information about blinding available, however personnel was aware of the
type of shunt being placed during the procedure. Outcomes were likely to be
unaffected by blinding.




events, quality of life
High risk No information about blinding available, however personnel was aware of the
type of shunt being placed during the procedure.





Low risk No information about blinding available, however personnel was aware of the





High risk "Patients with no known problem but who were lost to follow up prior to 1
year postoperatively were eliminated from analysis." 4/47 participants were
lost in the Chhabra group and 7/43 participants were lost in the Codman
group. Unbalanced attrition (9% vs 16%)
Selective reporting (re-
porting bias)
Unclear risk No protocol available. Head circumference and ventricular size were assessed
at follow-up but they were not reported as outcomes (no information as to
whether they were prespecified).
Other bias Low risk No other sources of bias were detected.
Warf 2005  (Continued)
CSF: cerebrospinal fluid
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MEI: modified Evan's index
M/F: male/female
MRI: magnetic resonance imaging
NTD: neural tube defect




Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Agarwal 2018 Retrospective study that reviewed medical records
ASERNIP-S 2014 Health technology assessment of Miethke proSA® adjustable gravitational shunt
Baird 2014 Systematic review
Beez 2014 Retrospective study that reviewed medical records
Czosnyka 1990 Physiological study on valve mechanics
Czosnyka 2000 Letter
Czosnyka 2002 Physiological study on valve mechanics
Decq 1995 Retrospective study that reviewed medical records
Del Bigio 1998 Systematic review of in vitro studies
Drake 1996 Duplicate
Drake 1998a Narrative review
Drake 2000 Duplicate
Eymann 2007 Prospective study with no control group
Felix 1983 Prospective study with no control group
Gruber 1984 Prospective study with no control group
Haberl 2009 Prospective study with no control group
Higashi 1994 Case series comparing different valves
Hoshide 2017 Editorial
Ito 2012 Systematic review
Jain 2005 Case series
Kiefer 2000 Case series comparing different valves
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Study Reason for exclusion
Legat 1996 Non-randomised comparative study
Li 2017 Systematic review
Lund-Johansen 1994 Case series comparing different valves
Mbabazi-Kabachelor 2019 Randomised study that assessed the effects of antibiotic-impregnated shunts
Meling 2005 Prospective study with no control group
Portnoy 1976 In vitro study
Rasul 2012 Systematic review
Sainte-Rose 1993 Case series
Schatlo 2013 Retrospective study
Sinha 2012 Randomised trial of a shunt at different pressures
Smely 1997 Case series
Sotelo 2005 Wrong intervention (shunt of continuous flow did not include a valve device). Study population in-
cluded normotensive hydrocephalus.
Symss 2015 Retrospective study
Villeda 1997 Case series
Wong 2012 Systematic review
Xenos 2003 Observational study
Xu 2013 Systematic review
Xu 2013a Systematic review
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Standard valve vs anti-syphon valve




Statistical method Effect size
1.1 Mortality 1   Risk Difference (M-H, Random, 95% CI) Totals not selected
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M-H, Random, 95% CI
0.01 [-0.02 , 0.03]
Risk Difference
M-H, Random, 95% CI
-1 -0.5 0 0.5 1
Favours anti-syphon Favours standard
 
 
Comparison 2.   Di3erent types of standard valves





Statistical method Effect size
2.1 Treatment failure 2   Risk Ratio (M-H, Random, 95% CI) Totals not selected
2.2 Mortality 2   Risk Difference (M-H, Random, 95% CI) Totals not selected
 
 



















M-H, Random, 95% CI
0.41 [0.13 , 1.27]
1.17 [0.72 , 1.92]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours valve A Favours valve BFootnotes
(1) Valve A: standard distal cleft. Valve B: Hakim ball-in-cone.
(2) Valve A: Chabbra. Valve B: Codman-Hakim
 
 
























M-H, Random, 95% CI
0.09 [-0.00 , 0.18]
-0.03 [-0.19 , 0.13]
0.02 [-0.04 , 0.09]
Risk Difference
M-H, Random, 95% CI
-1 -0.5 0 0.5 1
Favours valve A Favours valve BFootnotes
(1) Valve A: standard distal cleft. Valve B: Hakim ball-in-cone.
(2) Late deaths: Valve A: Chabbra. Valve B: Codman-Hakim.
(3) Early deaths: Valve A: Chabbra. Valve B: Codman-Hakim.
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Comparison 3.   Standard valve versus constant flow valve




Statistical method Effect size
3.1 Treatment failure 1 229 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.79, 1.47]
 
 






Test for overall effect: Z = 0.46 (P = 0.65)



















M-H, Random, 95% CI
1.08 [0.79 , 1.47]
1.08 [0.79 , 1.47]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours standard valve Favours constant flow-v
 
 
Comparison 4.   Programmable valve versus non-programmable valve




Statistical method Effect size
4.1 Treatment failure 1 377 Risk Ratio (M-H, Random, 95% CI) 1.02 [0.84, 1.24]
4.2 Adverse events 1 377 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.44, 2.15]
 
 






Test for overall effect: Z = 0.18 (P = 0.86)



















M-H, Random, 95% CI
1.02 [0.84 , 1.24]
1.02 [0.84 , 1.24]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours other valves Favours standard valve
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Test for overall effect: Z = 0.07 (P = 0.94)



















M-H, Random, 95% CI
0.97 [0.44 , 2.15]
0.97 [0.44 , 2.15]
Risk Ratio
M-H, Random, 95% CI
0.01 0.1 1 10 100
Favours other valves Favours standard valve
 
 
A P P E N D I C E S
Appendix 1. Search strategies
 
Database and date Search algorithm
MEDLINE
Ovid MEDLINE(R)










3 1 or 2
4 (convention* adj3 (valve* or shunt*)).ti,ab. 
5 (traditional* adj3 (valve* or shunt*)).ti,ab. 
6 (conservativ* adj3 (valve* or shunt*)).ti,ab. 
7 (programm* adj3 (valve* or shunt*)).ti,ab. 
8 (standard* adj3 (valve* or shunt*)).ti,ab. 
9 (cerebrospinal* adj3 (valve* or shunt*)).ti,ab. 
10 (cerebro spinal* adj3 (valve* or shunt*)).ti,ab. 
11 (ventriculoperiton* adj3 (valve* or shunt*)).ti,ab. 
12 (ventriculo periton* adj3 (valve* or shunt*)).ti,ab.
13 (pressure adj3 (valve* or shunt*)).ti,ab. 
14 (shunt* adj4 valve*).ti,ab. 
15 (endosc* adj3 ventriculost*).ti,ab. 
16 (gravitat* adj3 value*).ti,ab. 
17 ventriculost*.ti,ab. 
18 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 (11754)
19 exp Cerebrospinal Fluid Shunts/ 
20 exp Surgical Instruments/ 
21 exp Equipment Design/ 
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22 19 or 20 or 21 
23 18 or 22 





29 25 or 26 or 27 or 28 
30 24 and 29 
31 Randomized Controlled Trial.pt. 







39 31 or 32 or 33 or 34 or 35 or 36 or 37 or 38 
40 Animals/ not (Humans/ and Animals/) 
41 39 not 40 






#3 #1 or #2 
#4 (valve* or shunt*):ti,ab 
#5 (ventriculost*):ti,ab 
#6 depps 
#7 #4 or #5 or #6 
#8 MeSH descriptor: [Cerebrospinal Fluid Shunts] explode all trees 
#9 MeSH descriptor: [Equipment Design] explode all trees 
#10 MeSH descriptor: [Surgical Instruments] explode all trees 
#11 #8 or #9 or #10 
#12 #7 or #11 
#13 #3 and #12 
  (Continued)
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Cochrane Reviews matching "#13 - #3 AND #12"
Cochrane Database of Systematic Reviews
Issue 2 of 12, February 2020
Cochrane Protocols matching "#13 - #3 AND #12"
Cochrane Database of Systematic Reviews
Issue 2 of 12, February 2020
Trials matching "#13 - #3 AND #12"
Cochrane Central Register of Controlled Trials
Issue 2 of 12, February 2020
Editorials matching "#13 - #3 AND #12"
Cochrane Database of Systematic Reviews
Special collections matching "#13 - #3 AND #12"







3 1 or 2
4 (convention* adj3 (valve* or shunt*)).ti,ab.
5 (cerebrospinal* adj3 (valve* or shunt*)).ti,ab.
6 (cerebro spinal* adj3 (valve* or shunt*)).ti,ab.
7 (ventriculoperiton* adj3 (valve* or shunt*)).ti,ab.
8 (ventriculo periton* adj3 (valve* or shunt*)).ti,ab.
9 (conservativ* adj3 (valve* or shunt*)).ti,ab.
10 (traditional* adj3 (valve* or shunt*)).ti,ab.
11 (standard* adj3 (valve* or shunt*)).ti,ab.
12 (programm* adj3 (valve* or shunt*)).ti,ab.
13 (pressure adj3 (valve* or shunt*)).ti,ab.
14 (shunt* adj4 valve*).ti,ab.
15 DEPSS*.ti,ab.
16 (endosc* adj3 ventriculost*).ti,ab.
17 (gravitat* adj3 value*).ti,ab.
18 ventriculost*.ti,ab.
19 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17
or 18
20 exp cerebrospinal fluid shunting/
  (Continued)
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21 exp equipment design/
22 exp surgical equipment/
23 20 or 21 or 22
24 19 or 23
25 3 and 24






32 (MEDLINE and CENTRAL).ti,ab.
33 26 or 27 or 28 or 29 or 30 or 31 or 32
34 25 and 33
35 random*.tw. or placebo*.mp. or double blind*.mp.
36 25 and 35




(tw:((mh:(hidrocefalia )) OR (tw:(hidrocefal$ OR hydrocephal$)) )) AND (tw:((tw:((tw:((tw:(conven-
cion$ OR convention$ OR traditional$ OR tradicional$ OR conserv$ OR program$ OR standard$
OR estandar$ OR cerebrospinal$ OR cerebro spinal$ OR cefalorraquid$ OR cefalo raquid$ OR ven-
triculoperiton$ OR ventriculo periton$ OR presion$ OR pressure$ )) AND (tw:(shunt$ OR valv$ OR
deriv$)))) OR (tw:((tw:(shunt$ OR deriv$)) AND (tw:(valv$ )))) OR (tw:((tw:(endosc$)) AND (tw:(ven-
triculost$)))) OR (tw:((tw:(gravita$)) AND (tw:(value$ OR valor$)))) OR (tw:((tw:(ventriculost$))))))














#3 #1 OR #2 
#4 (convention* NEAR/3 (valve* OR shunt*)):ti,ab 
#5 (cerebrospinal* NEAR/3 (valve* OR shunt*)):ti,ab 
#6 (cerebro NEXT/1 spinal* NEAR/3 (valve* OR shunt*)):ti,ab 
#7 (ventriculoperiton* NEAR/3 (valve* OR shunt*)):ti,ab 
  (Continued)
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#8 (ventriculo NEXT/1 periton* NEAR/3 (valve* OR shunt*)):ti,ab 
#9 (conservativ* NEAR/3 (valve* OR shunt*)):ti,ab 
#10 (traditional* NEAR/3 (valve* OR shunt*)):ti,ab 
#11 (standard* NEAR/3 (valve* OR shunt*)):ti,ab 
#12 (programm* NEAR/3 (valve* OR shunt*):ti,ab 
#13 (pressure NEAR/3 (valve* OR shunt*)):ti,ab 
#14 (shunt* NEAR/4 valve*):ti,ab 
#15 DEPSS*:ti,ab 
#16 (endosc* NEAR/3 ventriculost*):ti,ab 
#17 (gravitat* NEAR/3 value*):ti,ab 
#18 ventriculost*:ti,ab 
#19 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17
OR #18 
#20 ‘cerebrospinal fluid shunting’/exp 
#21 ‘equipment design’/exp 
#22 ‘surgical equipment’/exp 
#23 #20 OR #21 OR #22 
#24 #19 OR #23 
#25 #3 AND #24 
#26 ‘systematic review’/exp 
#27 ‘meta analysis’/exp 
#28 (systematic NEXT/1 review*):ti,ab 
#29 (meta NEXT/1 analys*):ti,ab 
#30 metaanalys*:ti,ab OR metanalys*:ti,ab OR 'meta analys*':ti,ab 
#31 cochrane:ti,ab 
#32 medline:ti,ab AND central:ti,ab 
#33 #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 
#34 #25 AND #33 
#35 random* OR placebo* OR double NEXT/1 blind* 





hydrocephal* AND (shunt* OR valve*)
 
  (Continued)
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Appendix 2. Abstracts proceedings
 
Conference Source
European Society of Pediatric Neurosurgery, May 2018 ESPN 2018
International Society of Pediatric Neurosurgery, October 2019 ISPN 2019
International Society of Pediatric Neurosurgery, October 2018 ISPN 2018
International Society of Pediatric Neurosurgery, October 2017 ISPN 2017
 
 
H I S T O R Y
Protocol first published: Issue 7, 2017
Review first published: Issue 6, 2020
C O N T R I B U T I O N S   O F   A U T H O R S
SAPM is the contact person with the editorial base and also the clinical specialist author on the review topic. He designed the protocol and
was responsible for the final draO of the review.
LIG and JVAF amended the protocol, extracted data and conducted the analysis, draOed the 'Summary of findings' table and wrote the
final draO of the review.
VV contributed to the draOing of the protocol and data extraction and analysis of the review.
AC contributed to the methods section.
VG designed and ran the searches, writing the respective methods and results sections.
All authors have reviewed and approved the final version of the protocol.







S O U R C E S   O F   S U P P O R T
Internal sources
• Centro Cochrane Instituto Universitario, Hospital Italiano de Buenos Aires, Argentina
Provided methodological support for the review
• Paediatric Neurosurgery Service, Department of Paedriatrics, Hospital Italiano de Buenos Aires, Argentina
Provided clinical support for the review
• Family and Community Medicine Service, Hospital Italiano de Buenos Aires, Argentina
Provided methodological support for the review
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External sources
• No sources of support supplied
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
Outcomes
Since we found an overlap in the causes of shunt failure and adverse events (morbidity leading to shunt revision), we redefined the primary
outcomes (and added the timing of outcome measurement) to avoid the overlap and maximise the use of informative data. Furthermore,
"mortality related to the procedure" was usually di@icult to assess. Therefore, we reported early mortality in order to avoid an inadequate
interpretation of the findings and maximise the use of data regarding mortality. The outcomes selected for the 'Summary of Findings'
tables were modified accordingly.
Search methods
The Trials Register of the Cochrane Multiple Sclerosis and Rare Diseases of the CNS Group includes controlled trials comparing alternative
forms of interventions used for multiple sclerosis and other demyelinating diseases. Therefore, it was not searched due to the absence
of records regarding hydrocephalus.
The Embase search strategy was adapted to the Elsevier platform due to a change in our access to the database. Both the previous strategy
(OVID) and the current one are available in Appendix 1. The new strategy does not use filters from the original protocol (Health Information
Research Unit (HIRU)).
The search engine for the source of grey literature of the New York Academy of Medicine Grey Literature Report (www.greylit.org) did not
allow us to combine search terms for a systematic search strategy.
Synthesis methods
We added a section on synthesis without meta-analysis in Data synthesis since most of the data were scarce and new guidelines on how to
conduct narrative synthesis of quantitative data emerged this last year. Therefore, we were unable to conduct predefined subgroup and
sensitivity analyses. Furthermore, we deleted the sentence "If we suspected that missing data are not missing randomly, we performed
sensitivity analyses by imputing outcomes to recreate the most extreme possible data sets, one reflecting the best-case scenario for the
experimental treatment and the other the worst-case scenario as described in Higgins 2008" since we did not impute data.
'Summary of findings' table
We added information on the available comparisons and the timing of outcome measurement.
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